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2Abstract: Tryptophan is metabolized primarily via the kynurenine pathway (KP), which 
involves several enzymes, including indoleamine 2,3-dioxygenase, tryptophan 2,3 
dioxygenase (TDO), kynurenine aminotransferases (KATs), kynurenine monooxygenase 
(KMO) etc. The majority of metabolites are neuroactive: some of them, such as kynurenic 
acid, show neuroprotective effects, while others contribute to free radical production, 
leading to neurodegeneration. Imbalance of the pathway is assumed to contribute to the 
development of several neurodegenerative diseases, psychiatric disorders, migraine and 
multiple sclerosis. 
Our aim was to summarize published data on genetic alterations of enzymes involved in the 
KP leading to disturbances of the pathway that can be related to different diseases.
To achieve this, a PubMed literature search was performed for publications on genetic 
alterations of the KP enzymes upto April 2017.
Several genetic alterations of the KP have been identified and have been proposed to be 
associated with diseases. Here we must emphasize that despite the large number of 
recognized genetic alterations, the number of firmly established causal relations with 
specific diseases is still small. The realization of this by those interested in the field is very 
important and finding such connections should be a major focus of related research.
Polymorphisms of the genes encoding the enzymes of the KP have been associated with 
autism, multiple sclerosis and schizophrenia, and were shown to affect the immune 
response of patients with bacterial meningitis, just to mention a few.
3To our knowledge, this is the first comprehensive review of the genetic alterations of the 
KP enzymes. We believe that the identification of genetic alterations underlying diseases 
has great value regarding both treatment and diagnostics in precision medicine, as this work 
can promote the understanding of pathological mechanisms, and might facilitate medicinal 
chemistry approaches to substitute missing components or correct the disturbed metabolite 
balance of KP.
Keywords: Tryptophan metabolism, kynurenines, metabolic enzymes, genetic alterations, 
polymorphism, metabolic disturbances
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aminotransferase; KMO, kynurenine monooxigenase; Trp, tryptophan; KYN, L-
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AA, anthranilic acid; XA, xanthurenic acid; 3-HAA, 3-hydroxyanthranilate; ACMSD, 
aminocarboxymuconate-semialdehyde decarboxylase; QUIN, quinolinic acid; NAD+, 
nicotinamide-adenine-dinucleotide; GWAS, genome wide association studies; SNP, single 
nucleotide polymorphisms; LPS, lipopolysaccharides; TNF, tumor necrosis factor; IFN, 
interferon; MDD, major depressive disorder; CD, Crohn’s disease; PDA, pancreatic ductal 
adenocarcinoma; TS, Tourette syndrome; ADHD, attention deficit hyperactivity disorder; 
GC, glucocorticoid; GRE, glucocorticoid responsive element; GR, glucocorticoid receptor; 
AADAT, aminoadipate aminotransferase; HD, Huntington’s disease; AD, Alzheimer’s 
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BM, bacterial meningitis; MIP-1αCCL3, macrophage inflammatory protein 1-alpha; MIP-
1βCCL4, macrophage inflammatory protein-1-beta; CSF, cerebrospinal fluid; HO-1, 
hemeoxygenase-1; NO-cGMP, nitric oxide - cyclic guanosine monophosphate; PFC, 
prefrontal cortex; PDS, postpartum depressive symptoms; 3-OHKYN, 3-
hydroxykynurenine; SHR, spontaneously hypertensive rat; 3-HAO, 3-hydroxyanthranilate 
3,4-dioxygenase; COGA, Collaborative Study on the Genetics of Alcoholism; FCMTE, 
familial cortical myoclonic tremor and epilepsy; WGS, whole genome sequencing
51. Introduction
A general overview of the kynurenine pathway
Most of the dietary tryptophan (Trp) not used for protein synthesis is metabolized via the 
kynurenine pathway (KP) [1]. The metabolites have a broad spectrum of biological actions, 
and have been connected to several diseases [2][3][4][5]. The KP is one branch of Trp 
metabolism; the other branch provides serotonin and melatonin (Fig. 1). The first step in the 
KP is the conversion of Trp to N-formyl-L-kynurenine, by tryptophan 2,3-dioxygenase 
(TDO) or indoleamine 2,3-dioxygenase (IDO). Formamidase converts N-formyl-L-
kynurenine to L-kynurenine (KYN), which can be further metabolized by three distinct 
pathways. Kynurenine aminotransferases (KATs) can convert KYN to kynurenic acid 
(KYNA), kynurenine 3-monooxygenase (KMO) can convert it to 3-hydroxykynurenine (3-
HK), while kynureninase (KYNU) converts it to anthranilic acid (AA). 3-HK is either 
processed by KATs to xanthurenic acid (XA), or degraded to 3-hydroxyanthranilate (3-
HAA), which is metabolized by 3-hydroxyanthranilate 3,4-dioxygenase to form 2-amino-3-
carboxymuconate semialdehyde (ACMS). ACMS can be processed for either synthesis of 
2-aminomuconate semialdehyde by aminocarboxymuconate-semialdehyde decarboxylase 
(ACMSD), or can form quinolinic acid (QUIN) by non-enzymatic cyclization. QUIN can 
be further metabolized for nicotinamide-adenine-dinucleotide (NAD+) synthesis, while 2-
aminomuconate semialdehyde can form picolinic acid or be subsequently processed to 
acetyl coenzyme A. 
Intensive research is focused on the effects and alterations of the different KP metabolites 
and enzymes, however information regarding genetic alterations of this pathway is scarce. 
6Our review aims to collect the data available on mutations and genetic alterations of the 
enzymes of the KP and reveal possible connections with various diseases. We will follow 
the metabolic route of Trp (Fig. 1) and collect the data available on the enzymes directly 
connected to the KP.
2. Genetic alterations of the genes of kynurenine pathway enzymes and their 
association with diseases
As a result of genome sequencing projects all genes encoding KP enzymes have been identified. 
Results of traditional human genetic analysis studies and targeted or non-targeted high 
throughput genome wide association (GWA) studies indicate that in seven genes which encode 
KP enzymes (IDO1/2, TDO2, KATII, KMO, KYNU, 3-HAO, ACMSD), alterations can be 
identified that might be causally linked to disease states. However, it has to be emphasized that 
the majority of the cases summarized here only indicate an association, and not a causal 
relationship, between the genetic alteration and the respective disease. Most of these alterations 
are single nucleotide polymorphisms (SNP) present in variable frequencies in different 
population groups. In some cases, the nucleotide changes are found within coding regions of KP 
genes and result in amino acid changes or early translational termination of the concerned protein 
product. Nucleotide alterations can also occur outside of exons. Polymorphisms affecting introns, 
promoters, enhancer and silencer regions can play a crucial role modulating gene expression both 
at the levels of transcription and translation. Single nucleotide changes in regulatory regions can 
result in elimination or formation of transcription factor binding sites and consequently these 
changes can alter the binding efficiency of DNA binding domains [6]. In a few cases nucleotide 
alterations outside of exons affect gene function by changing intronic regions and thus modifying 
mRNA splicing and/or translation. It is worth noting that deletions or duplications have not been 
7identified for any of the KP enzyme genes, which most probably reflects the essential functions 
this pathway performs.
Through the next sections we summarize data available on genetic alterations of genes of KP 
enzymes following the steps of the pathway. For each enzyme the description starts with a short 
introduction providing the enzyme function, protein size, gene designation, location, expression 
and/or other specifics.
2.1. Indoleamine-2,3-dioxygenases
IDO (EC 1.13.11.52) is the first enzyme of the KP. It catalyzes the conversion of Trp to N-
formyl-L-kynurenine together with TDO. In humans, two IDO enzymes, IDO1 and IDO2 have 
been identified [7][8]. They are very similar in structure and function but are expressed in 
different patterns. IDO1 was first isolated from rabbit small intestine by Yamamoto and Hayaishi 
in 1967 [9].
It can be found ubiquitously in all tissues [10]. It is expressed in several types of immune cells, 
such as macrophages, monocytes, dendritic cells and microglia [11].It is a 45 kDa protein of 403 
amino acids. The gene encoding it is on the short arm of the 8th chromosome (8p11.21). 
Similarly, in mice it is also coded on chromosome 8, while in rats it localizes to chromosome 16. 
In humans, the transcribed region extends to 26516 nucleotides and consists of 10 exons. The 
expression of the gene is induced by lipopolysaccharides (LPS), cytokines, tumor necrosis factors 
(TNFs) and interferons (IFNs), especially IFN-γ [12].
IDO1 is a heme enzyme located in the cytosol. It can convert various substrates, such as L-
tryptophan, 5-hydroxy-tryptophan, serotonin and melatonin [13][14][15]. The crystal structure of 
the human enzyme was reported in 2006 by Sugimoto and colleagues [16].
8The physiologic role of the IDO1 enzyme is to conduct immune activation in various states (Fig. 
2). Upregulation of the enzyme leads to Trp depletion, which inhibits the proliferation of bacteria 
and other virulent agents. However, the mechanism of the decrease in Trp levels and the role that 
IDO plays in infectious states is controversial. Recently Badawy et al. argued that under specific 
conditions such as pregnancy Trp in fact is not depleted, rather its uptake by immune cells is 
increased greatly. Therefore IDO exerts its immune-regulating effect via the production of 
kynurenine metabolites [17].
Another mechanism by which IDO1 affects immune response is by inducing T cells to 
differentiate into T regulatory cells, thus blocking T cell responses [18]. This might explain the 
diverse expression of IDO1 throughout the human body. The gene is highly expressed in tissues 
that are highly exposed to antigens, such as mucosal surfaces of the lung and the intestinal 
system, lymph nodes and spleen. Antigen-presenting cells such as macrophages and dendritic 
cells also express IDO1. The anti-inflammatory effect of IDO1 activity contributes to maintain 
the immune homeostasis of different tissues. Thus it is conceivable that impairment in the activity 
of IDO1 can lead to the development of autoimmune diseases [19]. IDO1 could be involved in 
the process of immune editing, thus contributing to the immune escape of tumors [20]. Tumor 
derived factors have been reported to cause the differentation of dendritic cells with altered 
function. Immature dendritic cells in the tumor microenvironment show high expression of IDO1 
[21]. The upregulation of IDO1 leads to a differentation shift towards regulatory T cells instead 
of effector T cells and natural killer cells, thus leading to immune tolerance [18]. High levels of 
IDO1 expression in placenta indicates the importance of the enzyme in the suppression of fetal 
rejection by suppressing the reactivity of maternal T cells [22]. 
9Until the discovery of the second IDO enzyme, ’IDO’ stood for what now is known as IDO1. By 
now a similar second enzyme has been recognized that is referred to as indoleamine 2,3-
dioxygenase-like protein, proto-indoleamine 2,3-dioxygenase, or most commonly indoleamine 
2,3-dioxygenase-2, IDO-2 or IDO2.  
IDO2 is structurally and functionally similar to IDO1, supporting the hypothesis that the two 
proteins are products of genes originated from duplication of a common ancestral IDO gene [23]. 
In all mammalian species two IDO genes (IDO1 and 2) can be found. IDO1 is thought to be 
specific to mammals, and the majority of lower vertebrate species possess only IDO2. However, 
IDO1 has also been found in several fish and two turtle species This suggests that gene 
duplication occurred before the divergence of vertebrates, and IDO1 was later lost in several 
lower vertebrate lineages [24]. This notion is further supported by the fact that in mammals IDO1 
and IDO2 are located next to each other – in case of humans on the short arm of chromosome 8. 
Despite their similar structures [25], IDO2 is significantly bigger as it is 81778 nucleotides long 
and consists of 11 exons. The regulation of the two genes is in some way coordinated, which is 
supported by the observation that the expression of IDO2 was found to be significantly decreased 
in IDO1 knockout mice. An explanation for this finding could be the loss of IDO2 regulatory 
elements in consequence of removal of the IDO1 gene region [7].
The product of the IDO2 gene is a 420 amino-acid protein, with a molecular weight of over 47 
kDa. IDO2 and IDO1 proteins show 43 % amino acid identity both in humans and mice [7]. 
Those residues which are critical for catalytic functions are conserved in the two proteins. In vitro 
studies suggest that IDO2 can convert the same substrates as IDO1 (L-tryptophan, D-tryptophan, 
5-hydroxy-tryptamine, tryptamine and serotonin), however, the catabolic efficiency of IDO2 is 
much lower than that of IDO1 [26]. Interestingly, the enzymatic parameters of invertebrate IDOs’ 
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are similar to those of vertebrate IDO2. This suggests that the common ancestral IDO was similar 
to the present IDO2s in respect to their low catalytic efficiency [24]. In the distal heme pocket of 
IDO1 a Ser residue (distal-Ser, which corresponds to Ser167 of human IDO1) was found to be 
conserved in all IDO1 enzymes and also in a lizard (green anole, Anolis carolinensis) IDO2. In 
contrast with that in other IDO2 enzymes at this position a Thr (distal-Thr) residue is found [24]. 
Considering that IDO1 has a higher affinity to L-Trp than IDO2, and IDO2 of the green anole 
lizard shows similar enzymatic parameters to mammalian IDO1, this distal-Ser change seems to 
be crucial in the conversion of IDO1 from a low efficiency enzyme to a moderate efficiency one 
[24]. Besides the distal-Ser, another residue suspected to be - perhaps the most - critical residue 
for the high affinity for L-Trp is the distal-Tyr, which corresponds to Tyr126 in the human IDO1 
[27]. 
IDO2 is expressed in the liver, kidney, epididymis and brain in mouse [7][28], and in the liver, 
kidney and specific tumors in humans [29].
2.1.1. Diseases related to the genetic alterations of indoleamine 2,3-dioxygenase genes
A large number of SNPs within the transcribed regions of IDO1 and IDO2 genes have been 
described. None of these are associated unequivocally with any disease, nonetheless linkage has 
been suggested between several SNPs and specific disease states (Fig. 1).
As IDO plays important roles in immune response, the effects of genetic changes in IDO genes 
were studied mostly in relation to diseases characterized by impaired immune function. It was 
suggested that in tumors elevated expression of IDO proteins can locally regulate the immune 
environment, enhancing immune tolerance and thus increasing the survival of cancer cells 
[18][19][20][21]. Similarly, moderation of immune functions can underlie the effects of IDO on 
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allogenic fetal rejection [22][30][31][32]. Changes in IDO function have also been reported in 
neurodegenerative diseases [33].
One of the main inducers of IDO1 is IFN-α, which is used in the treatment of patients suffering 
from chronic hepatitis C. Several earlier studies reported a decrease in blood Trp concentrations 
and increase of KYN in association with IFN-α induced depression, suggesting the role of IDO in 
the process [34][35].
In search of genetic variations that can be associated with the development of IFN-α provoked 
depressive symptoms, Galvão-de Almeida et al. investigated three SNPs of the IDO1 gene in 
2011. However, none of the investigated polymorphisms (rs3824259, rs10089084, and 
rs35099072) were found to be associated with the disease [36]. The following year, Smith and 
colleagues investigated four SNPs (rs9657182, rs7820268, rs3739319 and rs6991530) of the gene 
with the same aim [11]. They found that one of the investigated SNPs had a significant effect on 
the evolution of depressive symptoms of IFN-α treated Caucasian patients with major depressive 
disorder (MDD) [11]. The SNP rs9657182 is a C/T nucleotide change in the promoter region of 
the gene. The nucleotide change has not been proven to alter any transcription binding site. Still, 
theoretically it could lead to altered gene function either alone, or via the effects of other 
polymorphism which may be associated with it [11].
In light of the normal physiological functions of the enzyme, the involvement of IDO1 in 
autoimmune diseases has been investigated. The induction of IDO1 gene by pro-inflammatory 
stimuli results in Trp depletion and formation of KP metabolites, leading to the reduction of 
inflammation and the promotion of immune tolerance [37]. Consequently, impaired function of 
the enzyme might contribute to the development of autoimmune diseases. Guided by this notion 
the possible role of IDO1 have been investigated in Crohn’s disease (CD) and systemic sclerosis.
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Lee et al. [37] found that IDO1 polymorphisms were rare among patients with CD. Out of the six 
investigated polymorphisms, they detected four in a group of clinically phenotyped CD patients 
(Table 1). Their results indicate that patients carrying specific IDO1 SNPs are more prone to 
extraintestinal manifestations, such as uveitis and arthritis. Their observation was that the 
presence of minor alleles was associated with a more severe disease course. Among carriers of 
the SNPs, a lower KYN level and KYN/Trp ratio could be detected as compared to the control 
group, leading to the assumption that the detected polymorphisms in CD patients result in 
impaired IDO1 function [37]. This study also included polymorphisms of the structurally and 
functionally similar IDO2 gene. It was found that although SNPs of the gene were common 
among a group of patients suffering from CD, none of the investigated polymorphisms had effect 
on the severity of the disease [37].
IDO1 polymorphism can also be related to another autoimmune disease, systemic sclerosis. 
Tardito et al. investigated 5 SNPs of the IDO1 gene, of which one (rs7820268, a C/T change in 
intron 5) was found to be present at a significantly higher frequency among systemic sclerosis 
patients compared to the non-patient group [38]. In the carriers of the minor allele a decrease in 
the CD8+ regulatory T cell suppressing capacity could be detected, suggesting an association 
between this gene variant and regulatory T cell function [38].
The involvement of IDO in immunological mechanisms gave ground to the notion that the 
enzyme could be involved in the suppression of fetal rejection. Published data on this issue are 
however controversial. An earlier study by Munn and collegues reported that inhibition of 
tryptophan catabolism via the implementation of the IDO – inhibitor 1-methyl-tryptophan 
resulted in fetal loss in a mice model. This is supposedly due to the lack of the T cell proliferation 
suppressing effect of cells catabolizing tryptophan. As 1-methyl-tryptophan is a known IDO 
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inhibitor, it is likely that the above described fetal rejection was a consequence of maternal T cell 
proliferation due to the inhibition of IDO [22]. Interestingly, later Baban and colleagues found 
that IDO deficiency due to genetic manipulation did not affect pregnancy success in mice. They 
hypothesized that in IDO deficient mice IDO-independent mechanisms – such as the activation of 
another key enzyme of the KP, TDO – compensate for the lack of the enzyme. This notion was 
strengthened by the finding that assessment of the IDO inhibitor 1-methyl-tryptophan in IDO 
deficient animals did not cause changes in pregnancy outcomes on contrary to IDO – sufficient 
mice pregnancies [39]. Another interesting question that still needs to be elucidated is the 
question of the decrease in Trp level during pregnancy. Badawy and colleagues hypothesized that 
the decrease in the level of Trp is not due to the depletion of the amino acid but is the 
consequence of its augmented utilization by the cells of the immune system – similarly as in the 
case of infection. They claim that during pregnancy increased availability of maternal Trp is 
needed to fulfill the increased demand for protein synthesis by the fetus and the pregnant mother. 
Elevated maternal free plasma Trp is then utilized in the KP, ensuring the production of 
immunosuppressive kynurenine metabolites which support the maintenance of the balance of 
tolerance and immunity. Therefore immunosuppression is not achieved by Trp depletion itself, 
but by the increased utilization of the amino acid [17]. 
The findings of animal studies raised the question of the role of IDO during human pregnancy. 
One of the most serious and life-threatening conditions during human pregnancy is pre-
eclampsia. Its etiology has not been fully understood so far, but several environmental and 
genetic factors have been proposed to contribute to its evolvement. The findings that in the 
placenta of pre-eclamptic women IDO1 expression is reduced and a correlation can be observed 
between the severity of the illness and the activity of the enzyme [31][32] turned the attention to 
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the KP. Taking this into consideration, Nishizawa et al. investigated the possible association of 
19 SNPs of the IDO gene with pre-eclampsia [40]. However, none of the studied polymorphisms, 
each within the coding region of the gene, was found to be associated. The only genetic alteration 
that might be linked to the condition based upon this study was a four nucleotide deletion within 
the intronic region of the gene; however, it is unclear how this change affects expression of the 
gene, if at all [40]. 
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Table 1. Genetic alterations affecting the enzymes of the kynurenine pathway
Gene rs number
Base change/amino acid 
change
Localization in 
the gene
Change in 
enzyme 
function
Related disease Reference
IDO1
rs9657182 C>T(fwd) promoter region
IFN-α induced 
depressive symptoms 
in patients with 
Hepatitis C
[11]
rs35059413 C>T(rev)/Ala4Thr
diminishment in 
enzyme activity
Severity of Crohn's 
disease
[37]
rs35099072 C>T(rev)/Arg77His
C>A exon 7
9 base pair deletion exon 7
rs7820268 C>T(fwd) intron 5
Treg suppression 
is diminished
systemic sclerosis [38]
IDO2
rs2929115 C>T(rev) non-conserved 
region between 
26kb and 28 kb 
downstream 
from the 3’ end
Citalopram 
responsiveness in 
major depressive 
disorder
[45]
rs2929116 G>A
TDO2
G>T
intron 6 Tourette syndrome [49]
G>A
rs3755910 A>C (fwd) promoter region Autism [67]
c.491dup/premature stop 
codon
leads to a 
truncated protein 
(premature stop 
codon) Hyperserotoninemia [68]
G>C/Met108Ile
accelerated 
degradation of 
the enzyme
AADAT rs1480544 C>T (fwd)
exonic splicing 
silencer
elevated enzyme 
production
Immune response in 
bacterial meningitis
[78][81][80]
KMO
rs1053230
A>G (rev);C>T (fwd) 
/Arg452Cys
exon 15
schizophrenia, bipolar 
disorder, PDS
[93][94][96][97][86]
rs2275163 C>T (fwd) intronic region schizophrenia [93][90][94]
rs1053221 A>G (rev)
 utr region Sclerosis multiplex [99]
rs1053183 C>T (rev)
KYNU
rs606231307 A>G(fwd)/Thr198Ala exon 7 Xanthurenic aciduria [103]
rs9013 A>G(fwd)/Lys412Glu unknown
Essential hypertension
[106]
rs2304705 G>A(fwd)/Arg188Gln
enzyme activity 
reduced by 50 %
[107]
HAAO
rs375554 A>G (fwd)
Alcohol dependence 
accompanied with 
conduct disorder or 
suicide attempts
[109]
rs13027051 C >T(fwd)
intronic region
rs2374442 A>G (fwd)
rs3816184 A>G (fwd)
rs3816182 A>C (fwd)
rs737148 A>G (rev)
rs3816183 C>T/Ile37Val Hypospadiasis [110]
ACMSD
G>A/premature stop 
codon
leads to a 
truncated protein 
(premature stop 
codon)
Familial cortical 
myoclonic tremor and 
epilepsy
[113]
rs6710823 A>G(fwd) Parkinson's disease [115]
fwd/rev: allele reported to forward/reverse orientation to genome
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The controversial findings of animal experiments raised the question of the role of the enzyme in 
fetal rejection in humans. However, the examination of 10 SNPs among Iranian women suffering 
from recurrent spontaneous abortion revealed no linkage between the investigated 
polymorphisms and the disease [41].
Following the observation that IDO1 helps tumor cells to survive and proliferate by facilitating a 
local immunotolerant environment [20], Witkiewicz et al. investigated two polymorphisms of the 
functionally similar IDO2 gene in patients with pancreatic ductal adenocarcinomas (PDAs) [42]. 
The two polymorphisms they studied show high prevalence in the population and result in either 
complete or very severe decrease (90%) in the catalytic activity of IDO2 [8]. Based on a 
relatively small patient cohort in which the frequencies of these polymorphisms were comparable 
to that of the control group, they did not find any link between IDO2 genotype and PDA [42]. In 
other words, these SNPs do not increase the risk of PDA development. On the other hand, their 
results show that the majority of investigated patients had at least one wild-type or functioning 
allele. This observation gives support to the argument that the IDO inhibitor D-1-methyl-
tryptophan might be useful in treatment of PDA due to the inhibition of the anti-inflammatory 
effects of IDO [42]. However, this treatment should be preceded by genetic investigation of the 
patients to identify those with at least one active IDO2 allele. Furthermore, selectivity of the drug 
should also be taken into account. The question concerning the most potent IDO2 inhibitor 
remains to be answered. Several studies have found that L – 1 - methyl-tryptophan, the levo 
stereosisomer of D-1-methyl-tryptophan has a more effective inhibitory effect of IDO2 [43] [44].
Besides the above discussed diseases, the relation of the IDO genes and a common psychiatric 
disorder has also been examined. Cutler et al. studied the potential role for IDO1 and IDO2 in 
MDD treatment outcome [45]. They found that two polymorphisms of the IDO2 gene have effect 
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on the responsiveness to citalopram treatment in patients with MDD. The two polymorphisms 
(rs2929115 and rs2929116) should be considered as one marker, because they were found to be 
in very high linkage disequilibrium [45]. Both are in a non-conserved region between 26kb and 
28kb downstream from the 3’ end of IDO2. They are near to transcriptional binding sites and are 
surrounded by two histone modification sites, but the functional consequences of these 
polymorphisms have not been elucidated yet [46].
2.2. Tryptophan 2,3-dioxygenase
TDO enzyme (EC 1.13.11.11) is a 47 kDa protein of 403 amino acids. The encoding gene, TDO2 
is rather large, consisting of 65 669 nucleotides and containing 12 exons. It is located on the long 
arm of chromosome 4 in humans, while it is located on chromosome 3 in mice and on 
chromosome 2 in rats.
TDO is a homotetrameric heme enzyme that catabolizes the conversion of L-Trp to N-formyl-L-
kynurenine, which is a rate limiting step of the KP. Via this conversion the enzyme also 
modulates serotonin levels by reducing the amount of Trp available for synthesis of the 
neurotransmitter. TDO is found mainly in the liver, thus modulating the available quantity of Trp 
throughout the body. The expression of TDO is induced by glucocorticoid hormones and the 
enzyme is also regulated by the availability of its substrate, L-Trp [47].
As the serotoninergic system is involved in the modulation of mood, sleep, aggression and other 
states, TDO2 is a target of investigations in relation to psychiatric and neurological diseases 
characterized by changes in the circadian rhythm, behavior and the reward system.
2.2.1. Diseases related to the genetic alterations of Tryptophan 2,3-dioxygenase gene
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A study by Comings et al. showed significant decrease in the Trp levels and in the 
serotonin/platelet ratio of patients with Tourette syndrome (TS) [48]. A decline in the 
serotonin/platelet ratio was also detected in the parents of the patients. Similar metabolic changes 
were reported among patients with attention deficit hyperactivity disorder (ADHD) and their 
parents. The similar findings suggest the existence of a link between TS and ADHD [48]. The 
observed alterations of serotonin level and the inheritance pattern of TS indicate the possible 
underlying genetic alteration: variants of the TDO2 gene are possible candidates contributing to 
these disorders. Mutations causing higher expression level, or leading to an enzyme that is more 
prone to induction can be a culprit behind the excessive N-formyl-L-kynurenine formation, thus 
diverting Trp from serotonin synthesis [48].
Further studies by Comings et al. showed a significant association between two intronic TDO2 
polymorphisms (a G to T and a G to A change) and TS (Fig. 1). One of these SNPs (the G to A 
change) was found to be significantly associated with altered platelet serotonin levels as well 
[49].
In a more recent study from the same laboratory [50] 20 genes were investigated in patients with 
ADHD. As this disorder is likely to be multigenic, caused by additive effects of several genes 
[51], the 20 studied genes were grouped into three sets. Those with activities related to 
dopaminergic neurotransmission formed one group (6 of the investigated genes), those related to 
the noradrenergic neurotransmission another group (7 of the genes) and the remaining 6 genes 
each involved in serotoninergic neurotransmission formed the third group. One SNP was 
investigated for each gene in the study. For TDO2, it was a G to A nucleotide change in the 
intronic region of the gene. According to the results noradrenergic genes were more likely to 
contribute to the ADHD phenotype than genes belonging to the other two groups [50]. 
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Nonetheless this finding does not exclude the possibility that genetic alterations of the TDO2 
gene affect the manifestation of ADHD.
The involvement of serotoninergic neurotransmission in the function of the reward system 
underpins the search for possible associations of specific changes in TDO2 with drug abuse. 
Previous findings show an increase in brain serotonin levels due to nicotine exposure, and an 
increase in the level of the neurotransmitter during withdrawal [52][53]. Clinical data also 
showed beneficial effects of the serotonin re-uptake inhibitor Fluoxetine during the decrease of 
nicotine intake of smokers. By applying the medication, weight gain, a common consequence of 
increased food intake frequently accompanying cessation of smoking, could be decreased [54]. 
Based on this notion, it is hypothesized that impairment in serotoninergic neurotransmission 
contributes to the mood and appetite disturbances associated with nicotine withdrawal and 
therefore might have a role in drug dependence [49]. 
In another study Comings et al. [49] investigated the association of drug dependence and two 
intronic polymorphisms of the TDO2 gene. Both of these SNPs are in intron 6 and potentially 
cause alteration in a binding site of the YY-1 transcription factor [6]. One SNP is a G to T change 
at position 666, the other is a G to A change at position 663. Neither was, however, found to be 
associated with drug dependence [49].
Another unfortunately commonly used and abused drug in our society is alcohol. Changes in 
serotoninergic neurotransmission have been reported during acute ethanol administration. Shortly 
after alcohol intake, an induction of serotonin biosynthesis can be observed [55][56]. After 5-8 
hours, this is followed by TDO stimulation, which causes a decrease in the serotonin level and 
simultaneously increases KYN production [56][57][58]. The gene activation is believed to be 
transcriptionally mediated by glucocorticoids (GC). The promoter region of the human TDO2 
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gene contains four functional glucocorticoid responsive elements (GRE) [59], which can serve as 
target sites in this activation. Soichot et al. aimed to identify SNPs in the GREs of the TDO2 
promoter region that cause alterations in the transcription regulatory effects of GCs. They 
investigated the effects of 12 SNPs of the TDO2 promoter region, three of which were in putative 
GREs. In in vitro experiments under basal conditions (without glucocorticoid receptor (GR) over-
expression, or Dexamethasone exposure) the studied nucleotide changes did not cause significant 
differences in promoter activity. However, upon GR over-expression without, or combined with 
Dexamethasone exposure, a statistically significant difference in promoter activity could be 
observed [59]. The data suggest that these TDO2 polymorphisms exert their effects only during 
TDO2 gene activation. Since a similar pattern of gene activation changes has been observed also 
in the case of a polymorphism not located in a known GRE, this indicates the possibility of 
another, yet unexplored response element [59]. However, in contrast with results obtained in 
vitro, in vivo measurements did not reveal association between the polymorphisms and plasma 
KYN/Trp ratio, an indicator of TDO/IDO enzyme activity [59] (Table 2).
The findings regarding the effects of genetic alterations in the TDO2 promoter region serve as 
good examples to highlight the importance of SNPs localized outside coding regions and splicing 
sites. In this respect it should be emphasized that genetic alterations might have impact not only 
by changing protein structure and/or function. Polymorphisms affecting regulatory regions such 
as the promoter can lead to the elimination or the formation of transcription binding sites, thus 
altering the binding efficiency of DNA binding domains [6].
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Besides ADHD, TS and drug dependence, impairment in serotoninergic neurotransmission has 
been reported in autism as well. In patients suffering from the disease impairments in serotonin 
synthesis in the brain have been detected [60][61], and more than a third of patients seems to 
have elevated platelet serotonin levels [62]. The involvement of serotoninergic neurotransmission 
in the disease is also supported by studies showing that Trp depletion exacerbates symptoms in 
patients with autistic disorder [63][64]. Family and twin studies suggest a genetically determined 
predisposition to autism [65][66]. In light of these data, genes involved in serotonin metabolism 
are potential disease-causing factors. Since investigation of genetic alterations of the serotonin 
transporter gene did not result in an unambiguous answer [49], TDO2 arose as a potential 
candidate. Nabi et al. studied the presence of five TDO2 polymorphisms in families with 
members diagnosed with autism using transmission disequilibrium test [67]. Four polymorphisms 
included in the study are located in the promoter region of the gene, while one is at the 3’ slice 
region of exon 11. For one of the investigated nucleotide changes affecting the promoter region 
(rs3755910, an A/C change) a significant difference was found in the transmission to autistic 
Table 2. 
Identified SNPs in the human TDO2 promoter region
rs number base change
rs3755908 1605T>C 
rs3775085 1532A>C 
rs17033763 1471G>A 
Unknown 1342C>A 
rs3836580 1248_1247InsA 
rs10857287 1131A>G 
rs11935082 1059T>C 
rs60426490 935_933delGTT
Unknown 769T>G 
rs3775086 722T>A 
rs3755909 455C>T
s3755910 311C>A
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subjects. The more frequent C allele of the polymorphism was preferentially transmitted to 
family members with autistic disorders. This strongly suggests that though this SNP is not likely 
to be a risk factor in autism, it is in a strong linkage disequilibrium with another polymorphism 
associated with the disease that is so far unknown [67]. 
The role of TDO in Trp metabolism gives ground to the investigation of the enzyme not only in 
psychiatric disorders but in other Trp and serotonine related diseases. In a recent study Ferreira et 
al. reported a peculiar situation, in which a single patient was diagnosed with chronic 
hypertryptophanemia and hyperserotoninemia [68]. Sequencing of the TDO2 gene revealed the 
patient to be compound heterozygous for the c.491dup and c.324G>C variant of the TDO2 gene. 
The variant c.491dup (paternally inherited in the patient) causes a premature stop codon leading 
to the formation of a truncated protein, which is 43% of the normal length of TDO [68]. The 
c.324G>C gene variant (which was maternally inherited in this patient) leads to methionine to 
isoleucine change at the 108. amino acid of the protein. The expression level of the c.491dup 
variant mRNA was found to be similar to the wild type, as the transcription of the gene was not 
affected by this alteration. In vitro studies however showed that the truncated protein changed the 
catabolic activity of the enzyme [68]. 
The c.324G>C base change affects a specific site of the enzyme. Under normal conditions TDO 
has a short half-life which is regulated by the status of a non-catalytic Trp binding site. The 
enzyme activity and turnover depends on the occupancy of this binding site: when it is occupied 
it increases the catalytic activity, while when it is empty, it serves as a degradation signal [69]. 
The Met/Ile change resulting from the c.324G>C base change affects the formation of this non-
catalytic Trp binding site. According to in vitro data the activity of the enzyme is not affected 
[68], however, as a result of the amino acid change the binding affinity of the enzyme to its 
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substrate is significantly decreased, and consequently the degradation rate of the enzyme is 
increased [68]. Thus, the c.324G>C genetic alteration of the gene causes the accelerated 
degradation of the TDO enzyme [68]. In summary, according to Ferreira et al., the chronic 
hypertryptophanemia and hyperserotoninemia observed in this patient is a consequence of the 
combination of altered catabolic activity and accelerated degradation of TDO, both caused by 
single nucleotide genetic alteration of the TDO2 gene [68].
2.3. Kynurenine formamidase
Kynurenine formamidase/arylformamidase (EC 3.5.1.9) converts N-formyl-L-kynurenine to 
KYN. It is coded on chromosome 17, 10, 11 in humans, rats and mice, respectively (AFMID 
gene). Little is known about this enzyme - it seems that it has two isoforms in humans, one a 301 
AA and one a 303 AA form, and it is expressed in various tissues, but most abundant in liver and 
kidney [70]. To our knowledge, no specific alterations in the AFMID gene were directly 
correlated with any human disease.
2.4. Kynurenine aminotransferases
In human brain four KATs have been identified which catalyze KYNA synthesis (EC 2.6.1.7) 
[71]. These are glutamine transaminase K/cysteine conjugate beta-lyase 1 (KATI, EC 4.4.1.13), 
aminoadipate aminotransferase (KATII, EC 2.6.1.39), glutamine transaminase L/cysteine 
conjugate beta-lyase 2 (KATIII, EC 4.4.1.13), and glutamic-oxaloacetic transaminase 
2/mitochondrial aspartate aminotransferase (KATIV EC 2.6.1.1) [71]. They are multifunctional 
enzymes with broad substrate specificity, and function as homodimers with pyridoxal 5’-
phosphate as cofactor [71]. Besides the irreversible transamination of KYN to KYNA, they can 
catalyze the conversion of 3-HK to XA. In human brain, the principal enzyme responsible for the 
formation of KYNA is KAT II [72][73], therefore we will focus on this enzyme below.
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The KATII enzyme is a 47 kDa protein consisting of 425 amino acids. The aminoadipate 
aminotransferase (AADAT) gene encoding this protein is located on the long arm of chromosome 
4 in humans. It spans 31 478 nucleotides and contains 18 exons. The gene is located on 
chromosome 8 in mice and on chromosome 19 in rats.
In vitro studies show that KATII enzyme has very broad substrate specificity. Besides catalyzing 
the formation of KYNA from KYN, it catalyzes the transamination of α-aminoadipate and 
several other amino acids [74].
Alterations in the level of KYNA have been reported in several neurological diseases, such as 
Huntington’s disease (HD), Alzheimer’s disease (AD) [75] Parkinson’s disease (PD) [76] 
multiple sclerosis (MS) [77] and AIDS dementia. KYNA is a modulator of glutamatergic 
neurotransmission via its N-methyl-D-aspartate (NMDA) receptor antagonist effect and has 
neuroprotective features [74][75][76]. According to this, impairment in the synthesis of KYNA 
could thus contribute to the development of neurodegenerative diseases. Since KATII plays a 
crucial role in the formation of this neuroprotective agent, the enzyme has been mainly 
investigated in disorders related to neuronal damage.
2.4.1. Diseases related to the genetic alterations of aminoadipate aminotransferase gene
Predicated on previous studies reporting the involvement of the KP in inflammatory diseases, de 
Souza et al. [78] searched for genetic alterations affecting KP enzymes in patients with bacterial 
meningitis (BM) (Fig. 1). Two polymorphisms of the AADAT gene were included in the study: 
rs17852900, causing a G to T change, and rs1480544, a C/T change. The rs1480544 
polymorphism affects a putative regulatory element, an exonic splicing silencer - consequently it 
is thought to affect mRNA and peptide synthesis [79]. This polymorphism was found to be 
significantly more frequent in patients with BM considering both allelic and genotypic 
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frequencies. In patients homozygous for the minor allele (TT), a significant decrease was 
detected in the levels of tumor-necrosis factor alpha (TNF-α), interleukin 1 beta (IL1-β), 
macrophage inflammatory protein 1-alpha (MIP-1αCCL3), macrophage inflammatory protein-1-
beta (MIP-1βCCL4) and in the number of cells counted in the collected cerebrospinal fluid 
(CSF), and an increase in immunoglobulin G (IgG) levels. These findings suggest that the 
rs1480544 polymorphism causes impairment in the immune response against virulent agents. The 
C/T change in the exonic splicing silencer region of the gene supposedly affects the expression of 
inflammatory markers such as TNF-α, IL1-β, MIP1αCCL3 and MIP1βCCL4, and causes 
impairment in the recruitment of leukocytes. The elevation of IgG levels in patients with TT 
genotype suggests the influence of KYNA on immunoglobulin production, the mechanism of 
which, however, is so far unknown [78].
In addition to de Souza’s findings, Coutinho et al. found elevated KYNA levels in the CSF of 
patients with BM carrying the T allele of the rs1480544 polymorphism [80]. A tendency for 
increase in KYNA level was also noted among CT genotype patients suffering from acute BM. 
These results give support to the assumption that this particular SNP leads to an increase in the 
amount of AADAT mRNA and subsequently causes enhancement of KATII enzyme synthesis 
[80].
In 2015 Fontes et al. searched for possible combinations of genotypes that could have an effect 
on the course of BM [81]. Based on previous findings of de Souza et al., they examined the 
occurrence of the rs1480544 C/T variant of the AADAT gene in combination with polymorphisms 
of genes previously reported to cause impairment in DNA repair mechanisms, such as 
Asn148Glu of Apurinic/Apyrimidinic Endodeoxyribonuclease (APEX1), Ser326Cys of 8-
Oxoguanine DNA Glycosylase (OGG1) and Val762Al of Poly(ADP-Ribose) Polymerase 1 
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(PARP1). Results of gene interaction analysis showed a statistically significant combined 
occurrence of these genetic alterations among BM patients, suggesting the possibility of 
synergism existing between different pathways involving these genes in the development and 
course of BM [81].
2.5. Kynurenine 3-monooxygenase 
KMO (Kynurenine 3-monooxygenase, also known as Kynurenine 3-Hydroxylase) (EC 1.14.13.9) 
is a 55 kDa molecular mass protein of more than 480 amino acids. In the KP it catalyzes the 
KYN to 3-HK conversion. It is a mitochondrial flavoprotein, utilizing O2 and NADPH for the 
catalyzed reaction [82]. Downstream of KMO in the pathway, 3-HAA and QUIN are synthesized. 
Elevated levels of 3-HK, which is an endogenous oxidative stress generator, have been reported 
in several neurodegenerative disorders [77][83]. In contrast to 3-HK, 3-HAA may be 
neuroprotective due to its hemeoxygenase-1 (HO-1) inducing effects in astrocytes. HO-1 is an 
antioxidant enzyme with anti-inflammatory and cytoprotective features [84]. In the central 
nervous system QUIN acts as a neurotoxin, via activating NMDA receptors, thus creating an 
enormous calcium influx into astrocytes and neurons, causing cell damage [85]. QUIN has an 
effect on the appearance of depressive symptoms by inducing the nitric oxide - cyclic guanosine 
monophosphate (NO-cGMP) pathway, promoting oxidative stress and interfering with the 
translation of brain derived neurotrophic factor [86]. 
The KMO gene in humans is localized on the long arm of chromosome 1. It is 63 759 nucleotides 
long and consist of 17 exons. Kmo is coded on chromosome 13 in rat and on chromosome 1 in 
mice.
2.5.1. Diseases related to the genetic alterations of kynurenine 3-monooxygenase gene
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Several studies have reported linkage between genetic loci on the long arm of chromosome 1 and 
psychiatric disorders with psychotic symptoms, such as bipolar disorder and schizophrenia 
(Fig.1) [87][88][89]. Since the KMO gene is located at that locus, it became a candidate in the 
eye of researchers looking for a predisposing factor for the diseases mentioned above. Results 
obtained from postmortem tissue analysis of schizophrenic patients support this suspicion. A 
significant and correlated decrease in the expression of the KMO gene and the activity of the 
KMO enzyme was found in brain tissues obtained from schizophrenia patients compared to 
control patients [90]. Data concerning association between genetic alterations of the KMO gene 
and schizophrenia are, however, inconclusive, as no linkage could be identified between the 
presence of any one of 15 studied polymorphic forms of the gene in Scandinavian patients [91].
Among Japanese patients the association of the rs2275163 (a C/T change) polymorphism with 
schizophrenia was found to be significant both by single marker comparisons and haplotype 
analysis. However, among a second, independent sample the significance of haplotype 
association could not be reproduced [92].
Results are similar regarding the rs2275163 polymorphism among Russian patients – no 
significant difference was found between the frequency of the minor allele in patients and in 
healthy controls [93]. However, this study revealed a significant intergroup difference concerning 
another SNP, rs1053230. 
The polymorphism is an A/G base change in exon 15 of the KMO gene, causing an arginine to 
cysteine change at the 452nd amino acid of the enzyme (in fact the nucleotide change in the 
coding sequence is C/T, however the database records the SNP in reverse orientation). The 
frequency of the homozygous minor GG genotype of rs1053230 polymorphism was significantly 
higher among patients compared to the control group. Interestingly, though the minor allele (T) 
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of the other studied SNP rs2275163 did not prove to be a risk factor alone, in combination with 
the GG genotype of rs1053230 it seemed to increase the risk of schizophrenia. The risk of 
schizophrenia among subjects with the GG genotype of the rs1053230 locus combined with at 
least one minor allele of the SNP rs2275163 (either in the form of a CT or TT genotype) was 
shown to be twice as high as in subjects with a different allele combination [93]. Though data 
concerning the association of polymorphism rs2275163 with the incidence of schizophrenia are 
equivocal, it is likely that is has an impact on the expression of the KMO gene. In schizophrenic 
patients with at least one minor allele of the single nucleotide change rs2275163, a slightly higher 
KMO mRNA level could be detected compared to those who had CC genotype [90]. 
Patients homozygous for the major allele of rs2275163 (CC genotype) were found to perform 
more poorly in neurocognitive tasks such as predictive pursuit and visuospatial working memory 
than members of the CT genotype subgroup [94][90]. However, when comparing patients with 
CC and TT genotypes, the difference was not significant [90]. It should be mentioned here that 
among healthy subjects with TT or CT genotypes inequality could also be observed in cognitive 
performance, though the difference was again not significant [94]. 
Effects upon cognitive functions were also reported for homozygous carriers of the SNP 
rs1053230 major allele. Similarly to rs2275163, individuals of CC genotype regarding the SNP 
rs1053230 reached lower composite scores compared to the CT or TT genotype [94].
Based on the fact that elevated KYNA levels have been reported in the CSF of schizophrenic 
patients and KMO is in charge of the formation of 3-HK, thus decreasing the amount of KYN 
available for KYNA synthesis, changes in KYNA levels can serve as an indirect indicator of 
KMO activity [95]. Andreassen et al. found that both in control and schizophrenic patients the 
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presence of the T allele of the SNP rs1053230 (indicated in forward orientation) was associated 
with a 45% increase of KYNA level in the CSF [96].
Besides schizophrenia, KMO has been investigated in bipolar disorder and depression as well. A 
decrease in KMO gene expression was detected in the prefrontal cortex (PFC) of bipolar disorder 
patients with psychotic features compared to patients without psychotic features [97]. This 
observation is in accord with results of postmortem brain tissue analysis of schizophrenic 
patients. However, in contrast with results of studies carried out among schizophrenic patients, 
the C allele of the rs1053230 (forward) polymorphism was found to be more common among 
bipolar disorder patients with psychotic features. The major allele was also associated with higher 
KYNA level in the CSF of bipolar patients, accompanied with a reduction in KMO activity. 
HapMap3 project data analysis revealed that this allele is also associated with a reduction in the 
KMO expression detected in lymphoblastoid cell lines. The link between the C allele of the 
rs1053230 SNP and KMO gene expression can also be observed in epileptic patients [97].
The same polymorphism of KMO (rs1053230) was also found to be significantly associated with 
postpartum depressive symptoms (PDS) in Chinese women. AG genotype women with PDS were 
found to have significantly higher serum 3-HK concentration and 3-HK/KYN ratio compared to 
those with the GG genotype. These findings suggest the possibility of the rs1053230 SNP causing 
higher KMO activity [86].
Alongside psychiatric disorders, genetic alterations of the KMO gene have also been investigated 
in diseases involving neurodegeneration, such as PD and MS.
Török et al. investigated 4 polymorphisms of the KMO gene in search for a genetic link between 
the KP and PD. Two of the examined SNPs (rs2275163 and rs1053230) have been associated 
with psychiatric disorders in other studies (see above). Both (rs2050518 and rs6661244) are 
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localized in intronic regions of the gene; the former one of them is an A to T change (rs 
2050518), the latter is a C to T. Neither of these polymorphisms was found to be associated with 
PD in the population studied [98].
In search for genetic alterations contributing to MS, a focused GWA study was carried out 
targeting chromosome 1q43. Two polymorphisms, rs1053221 (A/G) and rs1053183 (C/T) located 
in the KMO gene were found to be in significant association with the disease [99].
2.6. Kynureninase/L-Kynurenine Hydrolase
In humans, KYNU (EC 3.7.1.3) catalyses the 3-HK/3-HAA conversion. It is expressed in several 
tissues, such as bone marrow and organs of the immune system, kidney and urinary bladder, lung, 
brain, but most abundantly in the liver. It is a large protein composed of 465 amino acids, with a 
molecular weight over 52 kDa. It functions as a homodimer requiring PLP as a cofactor [100]. 
The gene is almost 307 000 nucleotides long. It is located on the long arm of chromosome 2 at 
the 22.2 position and contains 21 exons in humans. In mice it localizes to chromosome 2, while 
in rats to chromosome 3.
2.6.1. Diseases related to the genetic alterations of kynureninase gene
In 2007 Christensen et al. reported a family with xanthurenic aciduria (also known as 
hydroxykynureninuria). The diagnosis was based on detection of large quantities of urinary 
excretion of XA, 3-hydroxykynurenine (3-OHKYN) and KYN in one child and one of his 
siblings (sibling 1). Slightly increased urinary excretion of 3-OHKYN of the mother, father and 
another sibling (sibling 4) was also detected, each observation suggesting the deficiency of 
KYNU. Analysis of the KYNU gene showed that both the proband and sibling 4 were 
homozygous for a minor allele of the rs606231307 polymorphism of the gene (Fig. 1), whereas 
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the parents and sibling 1 carried one minor and one major allele. The SNP is an A/G change in 
the 7 exon of the gene, and causes a threonine to alanine amino acid change at the 198 position. 
The alteration can cause impairment in KYNU function, thus leading to the metabolic changes 
listed above. Impairment in the enzymatic function of the KYNU enzyme has already been 
hypothesized to be the underlying cause of xanthurenic aciduria [101][102]; however, this was 
the first case establishing an association at molecular genetic level [103].
The involvement of the KP in blood pressure regulation has been confirmed in animal 
experiments. A 40 Hgmm decrease of mean arterial blood pressure could be reached in 
spontaneously hypertensive (SHR) rats – widely used as models for the investigation of human 
hypertension – by injecting KYNA into the rostral ventrolateral medulla of the animals, an area 
with a key role in regulating arterial blood pressure [104]. Mizutani et al. hypothesized that high 
blood pressure in SHR rats might be due to malfunction of one of the enzymes related to KYNA 
metabolism. Therefore, they investigated the Kynu gene of the SHR strain, and found an A to G 
change at the 1291 position in exon 16, resulting in an isoleucine to valine switch in the enzyme. 
Another nucleotide change – a G to A substitution – was reported in intron 11 [105]. Comparison 
of the Kynu mRNA levels in the brainstem of SHR animals and animals of a non-hypertensive 
strain revealed a higher expression level in rats of the SHR strain. These findings – in concert 
with earlier results of Ito et al. – strongly suggest that the reported genetic alterations of the Kynu 
gene have an impact on enzyme function and participate in the development of hypertension 
[105].
The discovery of such drastic effects of KYNA in SHR rats, raised questions regarding the 
relationship between blood pressure regulation and the KP in humans. In 2005 Zhang et al. 
examined 16 polymorphisms of the KYNU gene among patients diagnosed with essential 
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hypertension. An A/G change polymorphism, causing a lysine to glutamic acid change at the 412 
amino acid of the enzyme, was found to be significantly more frequent among hypertensive 
patients than in the control group, considering both allele- and genotype distribution [106].
In a more recent experiment of Zhang et al. a further polymorphism of the KYNU gene was found 
to be associated with essential hypertension. The SNP rs2304705 is a G to A base change, which 
leads to an Arg to Gln switch in the KYNU protein at the 188. amino acid position. The minor 
allele (GA and AA genotypes) was found to be significantly more frequent among patients than 
in the control group. The overwhelming majority of patients with GA genotype had hypertension 
in their family history (96,97%), while this ratio was remarkably smaller (50%) among the 
individuals of the control group. Those who carried the minor allele had significantly higher 
systolic and diastolic blood pressure, mean arterial pressure and serum creatinine levels compared 
to those who were homozygous to the major allele. Results of the genetic analysis of genotype-
discordant sibling-pairs were in accordance with the findings presented above. Those who carried 
the minor allele had significantly higher systolic and diastolic blood pressure compared to those 
who were homozygous to the major allele (GG genotype). In vitro studies also revealed the link 
between the rs2304705 polymorphism and reduced KYNU enzyme activity, with the finding that 
the Arg188Gln amino acid change diminished the enzyme activity by 50%. Interestingly this 
association could not be detected in the case of the Lys412Glu polymorphism despite its 
association with essential hypertension (see above) [107].
2.7. 3-hydroxyanthranilate 3,4-dioxygenase
The 3-hydroxyanthranilate 3,4-dioxygenase (3-HAO, EC 1.13.11.6) enzyme catalyzes the 
conversion of 3-HAA acid to acroleyl aminofumarate, which converts to QUIN through non-
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enzymatic cyclization. The gene of 3-HAO is also known as HAAO. It is localized at 2p21, with a 
length of over 26 000 bases, and it contains 11 exons.
The 286 amino acid enzyme has a molecular mass of 32 kDa. It is found in the cytosol as a 
monomer. 3-HAO can be found in several tissues throughout the body, among others in liver and 
kidney, and it is also expressed in low amounts in the central nervous system [108].
By the conversion of 3-HAA the enzyme decreases the amount of a neuroprotective metabolite 
while increases the amount of a product with neurotoxic properties. Therefore, not surprisingly, 
alterations of 3-HAO are found in diseases which are associated with the elevated levels of 
QUIN.2.7.1. Diseases related to the genetic alterations of 3-hydroxyanthranilate 3,4-
dioxygenase gene
Collaborative Study on the Genetics of Alcoholism (COGA) data have shown a linkage between 
the p14-q14.3 region of chromosome 2 and alcohol dependence combined with behavioral 
disorder or suicide attempts. Several of the genes found in this region have already been 
associated with the conditions mentioned above. One of these genes is HAAO. In a follow-up 
study of the COGA data, SNPs of the HAAO gene were investigated with respect to their linkage 
to alcohol dependence accompanied by behavioral disorder or suicide attempts. Out of the 13 
investigated polymorphisms, 6 (rs375554, rs13027051, rs2374442, rs3816184, rs3816182 and 
rs737148) were found to be significantly associated with the diseases (Fig.1) [109].
Another association of an HAAO SNP with a disease was identified by Geller et al. By GWA 
studies they found a significant association between the rs3816183 SNP of the HAAO gene and 
the occurrence of hypospadiasis. This disease is a birth defect, the development of which is 
caused by the contribution of both environmental and genetic risk factors have been identified 
[69]. The rs3816183 polymorphism of HAAO is a C to T change that causes an isoleucine to 
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valine change at the 37 amino acid position of the enzyme [110]. The mechanism by which this 
alteration results in the development of hypospadiasis remains to be elucidated.
2.8. Aminocarboxymuconate semialdehyde decarboxylase
The ACMSD (EC 4.1.1.45) is a 38 kDa protein composed of 336 amino acids. The encoding 
gene is located on the long arm of chromosome 2. It is 63 729 nucleotides long and comprises 13 
exons in humans. In mice is coded on chromosome 1 while in rat on chromosome 13.
The enzyme can be found in the kidney, liver and brain. It plays a crucial role in the conversion 
of ACMS to 2-aminomuconate-semialdehyde. In the event of impaired ACMSD function, the 
reaction shifts towards production of QUIN, and through its neurotoxic properties may contribute 
to the development and progression of diseases such as PD, HD, AD and epileptic seizures 
[13][111][112].
2.8.1. Diseases related to the genetic alterations of aminocarboxymuconate semialdehyde 
decarboxylase gene
Recently Martí-Massó et al. reported on a family suffering from familial cortical myoclonic 
tremor and epilepsy (FCMTE). Symptoms of the patients, such as epileptic seizures, tremor, gait 
disturbances and cognitive impairment – the latter ones symptoms often related to 
neurodegenerative diseases – turned the attention to the ACMSD gene [113]. Whole Genome 
Sequencing (WGS) revealed a mutation which results in a premature stop codon (Trp26Stop) 
(Fig. 1). Supported by findings of Fukuoka et al. [114], it is believed that this genetic alteration 
causes impairment in the enzymatic function. Due to decreased activity of the ACMSD enzyme, 
the pathway is shifted in the direction of QUIN formation. The excessive amount of QUIN can 
explain the symptoms of the patients, as elevated brain QUIN levels can lead to the development 
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of epileptic seizures and promote the loss of neurons. This leads to the conclusion that the 
Trp26Stop mutation of the ACMSD gene can be a causative genetic alteration in FCMTE [113].
Findings of Martí-Massó et al., specifically the association of ACMSD with the reported patients, 
support the hypothesis of the vulnerability of the nigrostriatal dopaminergic system to the 
alterations of this gene. This assumption raised after the meta-analysis of GWASs carried out in 
2011 by the International Parkinson Disease Genomics Consortium. The aim of the study was to 
reveal so far unidentified genetic risks for PD. A polymorphism in the ACMSD locus was found 
to have a significant impact on the risk of development of the neurodegenerative disease (Fig.1) 
[115].
3. Conclusion
The KP plays a pivotal role in the metabolism of Trp. Some of the enzymes of the pathway have 
multiple forms in different tissues of the human body.
In recent decades large amounts of data on the human genome have been accumulated. Results of 
traditional genetic analyses and targeted or non-targeted high throughput GWS revealed links 
between disease states and several variants of seven of the KP genes (IDO1/2, TDO2, KATII, 
KMO, KYNU, 3-HAO, ACMSD) which result in expression of KP enzymes in somewhat altered 
forms. However, the majority of these findings represent associations linking genetic constitution 
to disease, and the alterations in the affected genes are not yet proven to be direct causes of the 
diseases.
Genetic alterations of the IDO enzymes were found to be associated mainly with autoimmune 
diseases such as CD and systemic sclerosis and disorders related to MDD. Association was found 
between TDO2 gene polymorphisms, hypertryptophanaemia and psychiatric disorders. Similarly, 
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based on its chromosomal localization, a significant association has been established between 
variants of the KMO gene and such psychiatric disorders as schizophrenia, bipolar disorder and 
PDS. In relation to neurodegenerative diseases, a link between a KMO SNP and MS has been 
reported, however, the association of any KMO genetic variant to PD so far has not been 
uncovered. Variants of other genes coding for further KP enzymes have been implicated as well 
in numerous malfunctions: alterations of the gene encoding KATII were found to be associated 
with modified inflammatory mechanism, the role of KYNU was shown in essential hypertension 
and xanthurenicaciduria. Variations of the HAAO gene have been linked to alcohol dependence 
and - by an as yet unknown mechanism – to hypospadiasis. Finally, a mutation of the gene coding 
for the ACMSD enzyme was found in members of a family with FCMTE and polymorphism of 
this gene are also recognized as a risk factor in PD.
The genetic alterations leading to activity changes of the KP are mostly SNPs which are present 
in varying frequencies in different population groups. In some cases, the nucleotide change is 
found within the coding regions of KP gene and thus results in amino acid change or early 
translation termination. In a few known cases nucleotide alteration outside of an exon affects 
gene function either by modifying RNA splicing and/or translation, or by altering promoter 
structure, thereby affecting transcription intensity. In a particular case, a single nucleotide change 
of the TDO2 gene causes an amino acid change in a regulatory site of the protein, and leads to the 
accelerated degradation of the enzyme [68].
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There are only a handful of cases where the disease-associated genetic alterations can clearly be 
linked to a change in enzyme activity (Table 3). The importance of studies aimed at linking 
enzyme activity changes to genetic changes can be hardly overemphasized and further 
approaches targeting this are clearly warranted. Clarifying linkages between changes of enzyme 
kinetics and genetic alterations can open new opportunities in the identification of potential 
therapeutic targets.
In addition to well-known effects of KP metabolites, which primarily consist of modulation of 
immune and inflammatory responses and neurodegeneration, there are several diseases in which 
enzymes or metabolites of the pathway are known to or suspected to play roles. Therefore, 
knowledge on the large number of genetic alterations resulting in minor allele variants of genes 
Table 3. 
Genetic alterations of genes of KP enzymes that are suspected to be related to human diseases 
and cause changes in enzyme activity
Gene Polymorphism Effect Reference
IDO1 rs35059413 Crohn's disease patients with changes in the IDO1 gene 
showed diminished IDO1 enzymatic activity compared 
to healthy controls
[37]
rs35099072
C/A change in exon 7
9 base pair deletion in exon 7
rs7820268 Impaired Treg suppression in patients with systemic 
sclerosis
[38]
TDO2 G>C/Met108Ile Leads to a catalytically less efficient enzyme which is 
more prone to degradation in patients suffering from 
hyperserotoninaemia
[68]
c.491dup/premature stop 
codon
Leads to the formation of truncated protein in patients 
with hyperserotoninaemia
AADAT rs1480544 Patients with bacterial meningitis carrying the 
polymorphism had higher KYNA levels - this SNP 
putatively causes elevated enzyme production
[80]
KYNU rs2304705 This mutation can predispose to essential hypertension 
and was shown to cause a 50% decrease in the catalytic 
efficiency in vitro
[107]
ACMSD G/A change leading to 
premature stop codon
Leads to the formation of truncated protein in patients 
with Familial cortical myoclonic tremor and epilepsy
[113]
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encoding KP enzymes may provide valuable help in prediction, diagnosis and/or prognostication 
of some of these diseases. Although these SNPs are believed to be associated only with disease, 
we believe that the further accumulation of knowledge on such changes will lead to the 
recognition of more and more genetic alterations with causal role as well. Moreover, the 
detection of SNPs affecting KP enzymes might also help to identify these genes and their 
products as potential therapeutic targets. A summary of our current knowledge of these genetic 
alterations can be useful for those developing approaches for precision medicine in respect of 
both the diagnosis of diseases and implementing the most suitable therapeutic methods. 
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Figure legends
Figure 1.
An overview of the KP. The metabolites are indicated with full name. The names of the enzymes 
are given in abbreviated forms. Diseases for which association of genetic alteration(s) resulting in 
malfunction of a particular enzyme has been investigated are listed with references. (Bold: 
association have been found)
 Abbreviations: IDO1,2: Indoleamine-2,3-dioxygenase 1,2; TDO: Tryptophan 2,3-dioxygenase; 
KAT: Kynurenine aminotransferase; KMO: Kynurenine 3-monooxygenase / Kynurenine 3-
Hydroxylase; KYNU: Kynureninase/L-Kynurenine Hydrolase; 3-HAO: 3-hydroxyanthranilate 
3,4-dioxygenase; ACMSD: Aminocarboxymuconate semialdehyde decarboxylase/Picolinate 
carboxylase; NAD+: Nicotinamide adenine dinucleotide
Figure 2. 
The role of IDO1 in immune regulation
IDO1 expression can be enhanced by cytokines (IL-1, IL-2, IL-4, IL-13, TNFα, TGFβ, IFNα/β/γ) 
and lipopolysaccharides (LPS). IDO1 induction leads to a decrease in tryptophan amount and the 
formation of kynurenine metabolites. By activating regulatory T cells, and via the inhibition of 
effector T cells and natural killer cells, IDO1 plays an important role in the maintenance of 
immune homeostasis, tumor immunity and in the suppression of fetal rejection and 
autoimmunity.
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Abstract: Tryptophan is metabolized primarily via the kynurenine pathway (KP). The KP 
involves several enzymes, including indoleamine 2,3-dioxygenase, tryptophan 2,3 
dioxygenase (TDO2), kynurenine aminotransferases (KATs), kynurenine monooxigenase 
(KMO) etc. The majority of metabolites are neuroactive, some of them such as kynurenic 
acid show neuroprotective effects, while others, for example 3-hydroxy-L-kynurenine and 
quinolinic acid contribute to free radical production, leading to neurodegeneration. 
Impaired balance of the pathway is assumed to participate in the development of several 
diseases such as Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, 
psychiatric disorders, migraine and multiple sclerosis. 
The aim of this review is to summarize available literature data on genetic alterations of the 
KP, leading to disturbances of the pathway that can be related to different diseases.
To achieve this goal, literature search was executed regarding the genetic alterations of 
enzymes related to the KP until April 2017 based on PubMed.
Several genetic alterations of the KP were found, and suggested to be associated with 
diseases. Polymorphisms of the TDO2 gene can be associated with autism; KATII 
polymorphisms affect the immune response of patients with bacterial meningitis, mutations 
of the KMO gene can be associated with multiple sclerosis and cognitive functions in 
schizophrenia, just to mention a few.
To our knowledge, this is the first comprehensive review of the genetic alterations of the 
KP enzymes. This work can promote the understanding of the mechanisms underlying the 
connected diseases, and might facilitate medicinal chemistry approaches to substitute 
missing components or correct the disturbed metabolite balance of KP.
Keywords: Tryptophan metabolism, kynurenines, metabolic enzymes, genetic alterations, 
polymorphism, metabolic disturbances
1 Abbreviations
KP, kynurenine pathway; IDO, indoleamine 2,3-dioxygenase; TDO2, tryptophan 2,3 
dioxygenase; KAT, kynurenine aminotransferase; KMO, kynurenine monooxigenase; Trp, 
tryptophan; KYN, L-kynurenine; KYNA, kynurenic acid; 3-HK, 3-hydroxykynurenine; 
KYNU, kynureninase; AA, anthranilic acid; XA, xanthurenic acid; 3-HAA, 3-
hydroxyanthranilate; ACMSD, aminocarboxymuconate-semialdehyde decarboxylase; 
QUIN, quinolinic acid; NAD+, nicotinamide-adenine-dinucleotide; GWAS, genome wide 
association studies; SNP, single nucleotide polymorphisms; LPS, lipopolysaccharides; 
TNF, tumor necrosis factor; IFN, interferon; MDD, major depressive disorder; CD, Crohn’s 
disease; PDA, pancreatic ductal adenocarcinoma; TS, Tourette syndrome; ADHD, attention 
deficit hyperactivity disorder; GC, glucocorticoid; GRE, glucocorticoid responsive element; 
GR, glucocorticoid receptor; AADAT, aminoadipate aminotransferase; HD, Huntington’s 
disease; AD, Alzheimer’s disease; PD, Parkinson’s disease; MS, multiple sclerosis; NMDS, 
N-methyl-D-aspartate; BM, bacterial meningitis; MIP-1αCCL3, macrophage inflammatory 
protein 1-alpha; MIP-1βCCL4, macrophage inflammatory protein-1-beta; CSF, 
cerebrospinal fluid; HO-1, hemeoxygenase-1; NO-cGMP, nitric oxide - cyclic guanosine 
monophosphate; PFC, prefrontal cortex; PDS, postpartum depressive symptoms; 3-
OHKYN, 3-hydroxykynurenine; SHR, spontaneously hypertensive rat; 3-HAO, 3-
hydroxyanthranilate 3,4-dioxygenase; COGA, Collaborative Study on the Genetics of 
Alcoholism; FCMTE, familial cortical myoclonic tremor and epilepsy; WGS, whole 
genome sequencing
1. Introduction
A general overview of the kynurenine pathway
Most of the dietary tryptophan (Trp) not used for protein synthesis is metabolized via the 
kynurenine pathway (KP) [1]. The produced metabolites have broad biological actions, and 
were connected to several diseases [2][3][4][5]. The KP is one branch of Trp metabolism, 
the other branch provides serotonin, and melatonin (Fig. 1). The first step in the KP is the 
conversion of Trp to N-formyl-L-kynurenine, by tryptophan 2,3-dioxygenase (TDO2) or 
indoleamine 2,3-dioxygenase (IDO). Formamidase converts N-formyl-L-kynurenine to L-
kynurenine (KYN), which can be further metabolized by three distinct pathways. 
Kynurenine aminotransferases (KATs) can convert KYN to kynurenic acid (KYNA), 
kynurenine 3-monooxygenase (KMO) can convert it to 3-hydroxykynurenine (3-HK), 
while kynureninase (KYNU) converts it to anthranilic acid (AA). 3-HK is either processed 
by KATs to xanthurenic acid (XA), or degraded to 3-hydroxyanthranilate (3-HAA), which 
is metabolized by 3-hydroxyanthranilate 3,4-dioxygenase to form 2-amino-3-
carboxymuconate semialdehyde (ACMS). ACMS can be processed for either synthesis of 
2-aminomuconate semialdehyde by aminocarboxymuconate-semialdehyde decarboxylase 
(ACMSD), or can form quinolinic acid (QUIN) by non-enzymatic cyclization. QUIN can 
be further metabolized for nicotinamide-adenine-dinucleotide (NAD+) synthesis, while 2-
aminomuconate semialdehyde could form picolinic acid or be subsequently processed to 
acetyl coenzyme A. 
Intensive research is focused on the effects and alterations of the different KP metabolites 
and enzymes, however the information regarding genetic alterations of this pathway are 
scarce. The present review aims to collect the data available on mutations and genetic 
alterations of the enzymes of the KP, and reveal the possible connections with various 
diseases. We will follow the metabolic route of Trp (Fig. 1) and will collect the data 
available on the enzymes strictly connected to the KP.
2. Genetic alterations of the genes of kynurenine pathway enzymes and their 
association with diseases
Due to genome sequencing projects, all genes encoding KP enzymes have been identified. 
Results of traditional human genetic analysis studies and targeted or non-targeted high 
throughput genome wide association (GWA) studies indicate that in seven genes (IDO1/2, 
TDO2, KATII, KMO, KYNU, 3-HAO, ACMSD) which encode KP enzymes, alterations can be 
identified that might be causally linked to disease states. 
Most of these alterations are single nucleotide polymorphisms (SNP) present in variable 
frequencies in different population groups. In some cases, the nucleotide changes are found 
within coding regions of KP genes and result in amino acid changes or early translational 
termination of the concerned protein product. In a few cases nucleotide alterations outside of 
exons affect gene function either by changing intronic region and thus modifying mRNA splicing 
and/or translation, or by altering promoter structure and thus affecting transcription intensity. It is 
noteworthy that for none of the KP enzyme genes have been either deletion or duplication 
identified, which most probably reflects the essential functions this pathway performs.
Through the next sections we summarize data available on genetic alterations on genes of KP 
enzymes following the steps of the pathway. For each enzyme the description starts with a short 
introduction providing the enzyme function, protein size, gene designation, location, expression 
and/or other specifics.
2.1. Indoleamine-2,3-dioxygenases
IDO (EC 1.13.11.52) is the first enzyme of the KP. It catalyzes the conversion of Trp to N-
formyl-L-kynurenine together with TDO2. In human, two IDO enzymes, IDO1 and IDO2 have 
been identified [6][7]. They are very similar in structure and function, but are expressed in 
different patterns. IDO1 was first isolated from rabbit small intestine by Yamamoto and Hayaishi 
in 1967 [8].
IDO1 can be found ubiquitously in all tissues [9]. It is expressed in several immune cells, such as 
macrophages, monocytes, dendritic cells and microglia [10].
IDO1 is a 45 kDa protein of 403 amino acids. The gene encoding it is on the short arm of the 8th 
chromosome (8p11.21). Similarly, in mice it is also coded on chromosome 8, while in rats it 
localizes to chromosome 16. In humans, the transcribed region extends to 26516 nucleotides and 
consists of 10 exons. The expression of the gene is induced by lipopolysaccharides (LPS), 
cytokines, tumor necrosis factors (TNFs) and interferons (IFNs), especially IFN-γ [11].
IDO1 is a heme enzyme located in the cytosol. It can convert various substrates, such as L-
tryptophan, 5-hydroxy-tryptophan, serotonin and melatonin [12]. The crystal structure of the 
human enzyme was reported in 2006 by Sugimoto and colleagues [13].
The physiologic role of the IDO1 enzyme is conducting immune activation in various states (Fig. 
2). Upregulation of the enzyme leads to Trp depletion, by this manner the proliferation of bacteria 
and other virulent agents is inhibited. Another mechanism, by which IDO1 affects immune 
response, is inducing T cells to differentiate into T regulatory cells, this way blocking T cell 
responses [14]. This might explain the diverse expression of IDO1 throughout the human body. 
The gene is highly expressed in tissues that are highly exposed to antigens, such as mucosal 
surfaces of the lung and the intestinal system, lymph nodes and spleen. Antigen-presenting cells 
such as macrophages and dendritic cells also express IDO1. The anti-inflammatory effect of 
IDO1 activity contributes to maintain the immune-homeostasis of different tissues. Thus, it is 
conceivable, that impairment in the activity of IDO1 can lead to the development of autoimmune 
diseases [15]. IDO1 can be involved in the process of immune editing thus contributing to tumors 
escaping the immune system [16]. Tumor derived factors have been reported to cause the 
evolution of dendritic cells with altered function. Immature dendritic cells in the tumor 
microenvironment show high expression of IDO1 [17]. The upregulation of IDO1 leads to a shift 
in the direction of forming regulatory T cells instead of effector T cells and natural killer cells, 
thus leading to immune tolerance [14]. IDO1 high level expression in placenta implicates the 
importance of the enzyme in the suppression of fetal rejection, by suppressing the reactivity of 
maternal T cells [18]. 
Until the discovery of the second IDO enzyme, ’IDO’ stood for what now is known as IDO1. By 
now a similar second enzyme has been recognized that is referred to as indoleamine 2,3-
dioxygenase-like protein, proto-indoleamine 2,3-dioxygenase, or most commonly indoleamine 
2,3-dioxygenase-2, IDO-2 or IDO2.  
IDO2 is structurally and functionally similar to IDO1 supporting the hypothesis, that the two 
proteins are products of genes originated from duplication of an ancient proto-IDO gene [19]. 
The genes are located next to each other on the short arm of chromosome 8. Despite their similar 
structures [20], IDO2 is significantly bigger as it is 81778 nucleotides long and consists of 11 
exons. The regulation of the two genes is in some way coordinated, which notion is supported by 
the observation that the expression of IDO2 was found significantly decreased in IDO1 knockout 
mice. An explanation for this finding could be the loss of IDO2 regulatory elements in 
consequence of removal of IDO1 gene region [6].
The product of IDO2 gene is a 420 amino-acid protein, with a molecular weight of over 47 kDa. 
IDO2 and IDO1 proteins show 43 % amino acid identity both in humans and mice [6]. Those 
residues that are critical for catalytic functions are conserved in the two proteins. In vitro studies 
suggest, that IDO2 can convert the same substrates as IDO1 (L-tryptophan, D-tryptophan, 5-
hydroxy-tryptamine, tryptamine and serotonin), however, IDO2 catabolic efficiency is much 
lower than that of IDO1 [21]. IDO2 is expressed in the liver, kidney, epididymis and brain in 
mouse [6][22], and in the liver, kidney and specific tumors in humans [23].
2.1.1. Diseases related to the genetic alterations of indoleamine 2,3-dioxygenase genes
A large number of SNPs within the transcribed regions of IDO1 and IDO2 genes have been 
described. None of these are associated unequivocally with any disease, nonetheless linkage have 
been suggested between several SNPs and specific diseases states (Fig. 1).
As IDO plays important roles in immune response, the effects of genetic changes in IDO genes 
were studied mostly in relation to diseases characterized with impaired immune function. It was 
suggested that in tumors elevated expression of IDO proteins can locally regulate the immune 
environment, enhancing immune tolerance, this way increasing the survival of cancer cells 
[14][15][16][17]. Similarly, moderation of immune functions can underlay IDO enzymes 
demonstrated effects on allogenic fetal rejection [18][24][25][26]. Changes in IDO function have 
also been reported in neurodegenerative diseases [27].
One of the main inducers of IDO1 is IFN-α that is used in treatment of patients suffering from 
chronic hepatitis C. Several earlier studies reported a decrease in blood Trp concentrations and 
increase of KYN in association with IFN-α induced depression, suggesting the role of IDO in the 
process [28][29].
In 2011 Galvão-de Almeida et al. in search for genetic variations that can be associated to the 
development of IFN-α provoked depressive symptoms, investigated three SNPs of the IDO1 
gene. However, none of the investigated polymorphisms (rs3824259, rs10089084, and 
rs35099072) were found to be associated to the disease [30]. The following year, Smith and 
colleagues investigated four SNPs (rs9657182, rs7820268, rs3739319 and rs6991530) of the gene 
with the same aim [10]. They found that one of the investigated SNPs has a significant effect on 
the evolution of depressive symptoms of IFN-α treated Caucasian patients with major depressive 
disorder (MDD) [10]. The SNP rs9657182 is a C/T nucleotide change in the promoter region of 
the gene. The nucleotide change has not been proven to alter any transcription binding site. Still, 
theoretically it could lead to altered gene function either alone, or via the effects of other 
polymorphism that could associate to it [10].
In light of the normal physiological functions of the enzyme involvement of IDO1 in 
autoimmune diseases have been investigated. The induction of IDO1 gene by pro-inflammatory 
stimuli results in Trp depletion and formation of KP metabolites, leading to inflammation 
reduction and promoting immune tolerance [31]. Consequently, impaired function of the enzyme 
might contribute to the development of autoimmune diseases. 
Lee et al. [31] found, that IDO1 polymorphisms were rare among patients with Crohn’s disease 
(CD). Out of the six investigated polymorphisms, they detected four in a group of clinically 
phenotyped CD patients (Table 1). Their results indicate that patients carrying specific IDO1 
SNPs are more prone to extraintestinal manifestations, such as uveitis and arthritis. Their 
observation was that the presence of minor alleles was associated with a more severe disease 
course. As among the carriers of the SNPs a lower KYN level and KYN/Trp ratio could be 
detected as compared to the control, it can be assumed, that the detected polymorphisms in CD 
patients result in impaired IDO1 function [31]. This study included also polymorphisms of the 
structurally and functionally similar IDO2 gene. It was found, that though SNPs of the gene were 
common among a group of patients suffering from CD, none of the investigated polymorphisms 
had effect on the severity of the disease [31].
IDO1 polymorphism can also be related to another autoimmune disease, systemic sclerosis. 
Tardito et al. investigated 5 SNPs of the IDO1 gene, of which one (rs7820268, a C/T change in 
intron 5) was found to have a significantly higher frequency among systemic sclerosis patients 
compared to the non-patient group [32]. In the carriers of the minor allele a decrease in the CD8+ 
regulatory T cell suppressing capacity could be detected, suggesting the association between this 
gene variant and regulatory T cell function [32].
The role of IDO1 in the placenta for suppressing fetal rejection has been shown previously [18]. 
In the placenta of pre-eclamptic women IDO1 expression is reduced and a correlation can be 
observed between the severity of the illness and the activity of the enzyme [25][26]. Taking this 
into consideration, Nishizawa et al. investigated the possible association of 19 SNPs of the IDO 
gene with pre-eclampsia [33]. However, none of the studied polymorphisms, each within the 
coding region of the gene, was found to be associated. The only genetic alteration that might be 
linked to the disease based upon this study was a four-nucleotide deletion within the intronic 
region of the gene; however, it is unclear how does this change affect the gene expression, if it 
does at all [33]. 
Table 1. Genetic alterations affecting the enzymes of the kynurenine pathway
Gene rs number
Base change/amino acid 
change
Localization in 
the gene
Change in 
enzyme 
function
Related disease Reference
IDO 1
rs9657182 C>T(fwd) promoter region
IFN-α induced 
depressive symptoms 
in patients with 
Hepatitis C
[10]
rs35059413 C>T(rev)/Ala4Thr
diminishment in 
enzyme activity
Severity of Crohn's 
disease
[31]
rs35099072 C>T(rev)/Arg77His
C>A exon 7
9 base pair deletion exon 7
rs7820268 C>T(fwd) intron 5
Treg suppression 
is diminished
systemic sclerosis [32]
IDO2
rs2929115 C>T(rev) non-conserved 
region between 
26kb and 28 kb 
downstream 
from the 3’ end
Citalopram 
responsiveness in 
major depressive 
disorder
[36]
rs2929116 G>A
TDO2
G>T
intron 6 Tourette syndrome [40]
G>A
rs3755910 A>C (fwd) promoter region Autism [59]
c.491dup/premature stop 
codon
leads to a 
truncated protein 
(premature stop 
codon) Hyperserotoninemia [60]
G>C/Met108Ile
accelerated 
degradation of 
the enzyme
KAT II rs1480544 C>T (fwd)
exonic splicing 
silencer
elevated enzyme 
production
Immune response in 
bacterial meningitis
[71][74][73]
KMO
rs1053230
A>G (rev);C>T (fwd) 
/Arg452Cys
exon 15
schizophrenia, bipolar 
disorder, PDS
[86][87][89][90][79]
rs2275163 C>T (fwd) intronic region schizophrenia [86][83][87]
rs1053221 A>G (rev)
 utr region Sclerosis multiplex [92]
rs1053183 C>T (rev)
KYNU
rs606231307 A>G(fwd)/Thr198Ala exon 7 Xanthurenic aciduria [96]
rs9013 A>G(fwd)/Lys412Glu unknown
Essential hypertension
[99]
rs2304705 G>A(fwd)/Arg188Gln
enzyme activity 
reduced by 50 %
[100]
HAAO
rs375554 A>G (fwd)
Alcohol dependence 
accompanied with 
conduct disorder or 
suicide attempts
[102]
rs13027051 C >T(fwd)
intronic region
rs2374442 A>G (fwd)
rs3816184 A>G (fwd)
rs3816182 A>C (fwd)
rs737148 A>G (rev)
rs3816183 C>T/Ile37Val Hypospadiasis [103]
ACMSD
G>A/premature stop 
codon
leads to a 
truncated protein 
(premature stop 
codon)
Familial cortical 
myoclonic tremor and 
epilepsy
[106]
rs6710823 A>G(fwd) Parkinson's disease [108]
fwd/rev: allele reported to forward/reverse orientation to genome
The relation of IDO and the suppression of fetal rejection was also investigated by Amani et al 
[34]. The examination of 10 SNPs among Iranian women suffering from recurrent spontaneous 
abortion revealed no linkage between the investigated polymorphisms and the disease [34].
Following the observation, that IDO1 helps tumor cells to survive and proliferate by facilitating a 
local immunotolerant environment [16], Witkiewicz et al. investigated two polymorphisms of the 
functionally similar IDO2 gene in patients with pancreatic ductal adenocarcinomas (PDAs) [35]. 
The two polymorphisms they studied show high prevalence in the population and result in either 
complete- or a very severe decrease (90%) in the catalytic activity of IDO2 [7]. Based on a 
relatively small patient cohort in which the frequencies of these polymorphisms were comparable 
to that of in the control group, they did not find any link between IDO2 genotype and PDA [35]. 
In other words, these SNPs do not increase the risk of PDA development. On the other hand, their 
results show, that the majority of the investigated patients had at least one wild-type or 
functioning allele. This observation gives support to the argument that the IDO inhibitor D-1-
methyl-tryptophan might be useful in treatment of PDA due to the inhibition of anti-
inflammatory effects of IDO [35]. However, this treatment should be preceded by genetic 
investigation of the patients in order to identify those with at least one active IDO2 allele. 
Furthermore, selectivity of the drug should also be taken into account.
Cutler et al. studied the potential role for IDO1 and IDO2 in MDD treatment outcome [36]. They 
found that two polymorphisms of the IDO2 gene have effect on the responsiveness to citalopram 
treatment in patients with MDD. The two polymorphisms (rs2929115 and rs2929116) should be 
considered as one marker, because they were found to be in very high linkage disequilibrium 
[36]. Both of them are located in a non-conserved region between 26kb and 28kb downstream 
from the 3’ end of IDO2. They are near to transcriptional binding sites and are surrounded by two 
histone modification sites, but the functional consequences of these polymorphisms have not 
been elucidated yet [37].
2.2. Tryptophan 2,3-dioxygenase
TDO2 enzyme (EC 1.13.11.11) is a 47 kDa protein of 403 amino acids. The TDO2 gene is rather 
big, it consists of 65 669 nucleotides and contains 12 exons. It is located on the long arm of 
chromosome 4 in humans, while it is located on chromosome 3 in mice and on chromosome 2 in 
rats.
TDO2 is a homotetrameric heme enzyme that catabolizes the conversion of L-Trp to N-formyl-L-
kynurenine which is a rate limiting step of the KP. By this conversion, the enzyme modulates the 
serotonin level as well with the reduction of the amount of Trp available for the synthesis of the 
neurotransmitter. TDO2 is found mainly in the liver, thus modulating the available quantity of 
Trp throughout in the body. The expression of TDO2 is induced by glucocorticoid hormones and 
the enzyme is also regulated by the availability of its substrate, L-Trp [38].
As the serotoninergic system is involved in the modulation of mood, sleep, aggression etc., 
TDO2 is a target of investigations in relation to psychiatric and neurological diseases 
characterized by changes in the circadian rhythm, behavior and the reward system.
2.2.1. Diseases related to the genetic alterations of Tryptophan 2,3-dioxygenase gene
A study of Comings et al. showed significant decrease in the Trp levels and in the 
serotonin/platelet ratio of patients with Tourette syndrome (TS) [39]. A decline in the 
serotonin/platelet ratio was also detected in the parents of the patients. Similar metabolic changes 
were reported among patients with attention deficit hyperactivity disorder (ADHD) and their 
parents. The similar findings suggest the existence of a link between TS and ADHD [39]. The 
observed alterations of serotonin level and the inheritance pattern of TS indicate the possible 
underlying genetic alteration: variants of the TDO2 gene are possible candidates contributing to 
these disorders. Mutations causing higher expression level, or leading to an enzyme that is more 
prone to induction can be a culprit behind the excessive N-formyl-L-kynurenine formation, thus 
diverting Trp from serotonin synthesis [39].
Further studies by Comings et al. showed a significant association between two intronic TDO2 
polymorphisms (an G to T and an G to A change) and TS (Fig. 1). One of these SNPs (the G to A 
change) was found to be in a significant association with changed platelet serotonin levels, as 
well [40].
In a more recent study from the same laboratory [41] 20 genes were investigated in patients with 
ADHD. As this disorder is likely to be multigenic, caused by as an additive effect of several 
genes [42], the 20 studied genes were grouped into three assemblies. Those which activities are 
related to dopaminergic neurotransmission formed one group (6 of the investigated genes), those 
related to the noradrenergic neurotransmission another group (7 of the genes) and the remaining 6 
genes each involved in serotoninergic neurotransmission formed the third group. For each gene 
the investigation of one SNP was included in the study. For TDO2, it was a G to A nucleotide 
change in the intronic region of the gene. According to the results noradrenergic genes 
contributed more likely to the ADHD phenotype than genes belonging to the other two groups 
[41]. Nonetheless this finding does not exclude the possibility that genetic alterations of the 
TDO2 gene affect the manifestation of ADHD.
The involvement of the serotoninergic neurotransmission in the function of the reward system 
gives reason to search for whether specific changes in TDO2 might be associated with drug 
abuse. Previous findings show an increase in brain serotonin levels due to nicotine exposure, and 
an increase in the level of the neurotransmitter during withdrawal [43][44]. Clinical data also 
showed beneficial effects of the serotonin re-uptake inhibitor Fluoxetine during the decrease of 
nicotine intake of smokers. By applying the medication, weight gain, a common consequence of 
increased food intake frequently accompanying cessation of smoking, could be decreased [45]. 
Based on this notion, it is hypothesized, that impairment in serotoninergic neurotransmission 
contributes to the mood- and appetite disturbances during nicotine withdrawal and therefore 
might have a role in drug dependence [40]. 
In another study Comings et al. [40] investigated the association of drug dependence and two 
intronic polymorphisms of the TDO2 gene. Both of these SNPs are in intron 6 and potentially 
cause alteration in a binding site of the YY-1 transcription factor [46]. One SNP is a G to T 
change at position 666, the other one is a G to A change at position 663. None of them was, 
however, found to be in association with drug dependence [40].
Another, unfortunately commonly used and abused drug in our society is alcohol. Changes in the 
serotoninergic neurotransmission have been reported during acute ethanol administration. Shortly 
after alcohol intake, an induction of the serotonin biosynthesis can be observed [47][48]. After 5-
8 hours, this is followed by TDO2 stimulation, that causes a decrease in the serotonin level and 
simultaneously increases kynurenine production [48][49][50]. The gene activation is believed to 
be transcriptional mediated by glucocorticoids (GC). The promoter region of the human TDO2 
gene contains four functional glucocorticoid responsive elements (GRE) [51], which can serve as 
target sites in this activation. Soichot et al. aimed at identifying SNPs in the GREs of the TDO2 
promoter region that cause alterations in the transcription regulatory effects of GCs. They 
investigated the effects of 12 SNPs of the TDO2 promoter region, three of which were in putative 
GREs. In in vitro experiments under basal conditions (without glucocorticoid receptor (GR) over-
expression, or Dexamethasone exposure) the studied nucleotide changes did not cause significant 
differences in promoter activity. However, upon GR over-expression without, or combined with 
Dexamethasone exposure a statistically significant difference in promoter activity could be 
observed [51]. The data suggest, that these TDO2 polymorphisms exert their effects only during 
TDO2 gene activation. Since similar pattern of gene activation changes has been observed also in 
the case of a polymorphism not located in a known GRE, this indicates the possibility of another, 
yet unexplored response element [51]. However, in contrast with results obtained in vitro, in vivo 
measurements did not reveal association between the polymorphisms and plasma KYN/Trp ratio, 
an indicator of TDO2/IDO enzyme activity [51] (Table 2).
The findings regarding the effects of genetic alterations in the TDO2 promoter region serve as 
good examples to highlight the importance of SNPs localized outside coding regions and splicing 
sites. In this respect it should be emphasized, that genetic alterations might have impact not only 
by changing protein structure and/or function. 
Table 2. 
Identified SNPs in the human TDO2 promoter region
rs number base change
rs3755908 1605T>C 
rs3775085 1532A>C 
rs17033763 1471G>A 
Unknown 1342C>A 
rs3836580 1248_1247InsA 
rs10857287 1131A>G 
rs11935082 1059T>C 
rs60426490 935_933delGTT
Unknown 769T>G 
rs3775086 722T>A 
rs3755909 455C>T
s3755910 311C>A
Polymorphisms affecting introns, promoters, enhancer- and silencer regions can play a crucial 
role modulating gene expression both at the levels of transcription and translation. Single 
nucleotide changes in regulatory regions can result in elimination or formation of transcription 
factor binding sites and consequently these changes can alter the binding efficiency of DNA 
binding domains [46].
Impairment in the serotoninergic neurotransmission has been reported in autism as well. In 
patients suffering from the disease impairments in serotonin synthesis in the brain have been 
detected [52][53], and more, than a third of the patients seems to have elevated platelet serotonin 
levels [54]. The involvement of serotoninergic neurotransmission in the disease is also supported 
by studies showing that Trp depletion exacerbates symptoms in patients with autistic disorder 
[55][56]. Family and twin studies suggest a genetically determined predisposition to autism 
[57][58]. In light of these data, genes involved in serotonin metabolism are potential disease 
causing factors. Since investigation of genetic alterations of the serotonin transporter gene did not 
result in an unambiguous answer [40], TDO2 arose as a potential candidate. Nabi et al. studied 
the presence of five TDO2 polymorphisms in families with members diagnosed with autism 
using transmission disequilibrium test [59]. Four polymorphisms included in the study are located 
in the promoter region of the gene, while one is at the 3’ slice region of the 11 exon. For one of 
the investigated nucleotide changes affecting the promoter region (rs3755910, an A/C change) a 
significant difference was found in the transmission to autistic subjects. The more frequent C 
allele of the polymorphism was preferentially transmitted to family members with autistic 
disorders. This strongly suggests, that though this SNP is not likely to be a risk factor in autism, it 
is in a strong linkage disequilibrium with another polymorphism associated with the disease, that 
is so far unknown [59]. (Table 3)
In a recent study Ferreira et al. reported a peculiar situation, in which a single patient was 
diagnosed with chronic hypertryptophanemia and hyperserotoninemia [60]. Sequencing of the 
TDO2 gene revealed the patient to be compound heterozygous for the c.491dup and c.324G>C 
variant of the TDO2 gene. The variant c.491dup (paternally inherited in the patient) causes a 
premature stop codon leading to the formation of a truncated protein, which is 43% of the normal 
length of TDO2 [60]. The c.324G>C gene variant (which was maternally inherited in this patient) 
leads to methionine to isoleucine change at the 108. Amino acid of the protein. The expression 
level of the c.491dup variant mRNA was found similar to the wild- type, such as the transcription 
of the gene was not affected by this alteration. In vitro studies however showed, that the truncated 
protein changed the catabolic activity of the enzyme [60]. 
The c.324G>C base change affects a specific site of the enzyme. Under normal condition TDO2 
has a short half-life which is regulated by the status of a non-catalytic Trp binding site. The 
enzyme activity and turnover depends on the occupancy of this binding site, when it is occupied 
it increases the catalytic activity, while when it is empty, it serves as a degradation signal [61]. 
The Met/Ile change resulting from the c.324G>C base change affects the formation of this non-
catalytic Trp binding site. According to in vitro data the activity of the enzyme is not affected 
Table 3. 
Investigated SNPs by Nabi et al
rs number base change localization
rs3755910 C/A promoter
rs3775085 A/C promoter
rs3755907 A/G promoter
rs3755908 C/T promoter
rs2292537 A/G 11 exon 3' splice region
[60], however, as a result of the amino acid change the binding affinity of the enzyme to its 
substrate is significantly decreased, and consequently the degradation rate of the enzyme is 
increased [60]. Thus, the c.324G>C genetic alteration of the gene causes the accelerated 
degradation of the TDO2 enzyme [60]. 
In summary, according to Ferreira et al., the chronic hypertryptophanemia and 
hyperserotoninemia observed in this patient is a consequence of the combination of altered 
catabolic activity and accelerated degradation of TDO2, both caused by single nucleotide genetic 
alteration of the TDO2 gene [60].
2.3. Kynurenine formamidase
Kynurenine formamidase/arylformamidase (EC 3.5.1.9) converts N-formyl-L-kynurenine to L-
kynurenine. It is coded on chromosome 17, 10, 11 in humans, rats and mice, respectively 
(AFMID gene). Little is known about this enzyme, it seems that it has two isoforms in humans, 
one 301 AA and one 303 AA form, it is expressed in various tissues, but most abundant, in liver 
and kidney [62]. To our knowledge, no specific alterations in the AFMID gene were directly 
correlated to any human disease.
2.4. Kynurenine aminotransferases
In human brain four KATs have been identified to catalyze KYNA synthesis (EC 2.6.1.7) [63]. 
These are glutamine transaminase K/cysteine conjugate beta-lyase 1 (KATI, EC 4.4.1.13), 
aminoadipate aminotransferase (KATII, EC 2.6.1.39), glutamine transaminase L/cysteine 
conjugate beta-lyase 2 (KATIII, EC 4.4.1.13), and glutamic-oxaloacetic transaminase 
2/mitochondrial aspartate aminotransferase (KATIV EC 2.6.1.1) [63]. They are multifunctional 
enzymes with broad substrate specificity, function as homodimers with pyridoxal 5’-phosphate as 
cofactor [63]. Besides the irreversible transamination of KYN to KYNA, they can catalyze the 
conversion of 3-HK to XA. In human brain, the principal enzyme responsible for the formation of 
KYNA is KAT II [64][65], therefore we will focus on this enzyme thereafter.
The KATII enzyme is a 47 kDa protein, consisting of 425 amino acids. The aminoadipate 
aminotransferase (AADAT) gene encoding this protein is located on the long arm of chromosome 
4 in humans. It spans 31 478 nucleotides and contains 18 exons. The gene is located on 
chromosome 8 in mice and on chromosome 19 in rats.
In vitro studies show, that KATII enzyme has very broad substrate specificity. Besides catalyzing 
the formation of KYNA from L-formyl-N-kynurenine, it catalyzes the transamination of α-
aminoadipate, and several other amino acids [66].
Alterations in the level of KYNA have been reported in several neurological diseases, such as 
Huntington’s disease (HD), Alzheimer’s disease (AD) [67] Parkinson’s disease (PD) [68] 
multiple sclerosis (MS) [69] and AIDS dementia. KYNA is a modulator of glutamatergic 
neurotransmission via its N-methyl-D-aspartate (NMDA) receptor antagonist effect and has 
neuroprotective features [66][67][68]. According to this, impairment in the synthesis of KYNA 
could contribute to the development of neurodegenerative diseases. Since KATII plays a crucial 
role in the formation of this neuroprotective agent, the enzyme has been mainly investigated in 
disorders related to neuronal damages [70].
2.4.1. Diseases related to the genetic alterations of aminoadipate aminotransferase gene
Predicated on previous studies reporting the involvement of the KP in inflammatory diseases de 
Souza et al. [71] searched for genetic alterations affecting KP enzymes in patients with bacterial 
meningitis (BM) (Fig. 1). Two polymorphisms of the AADAT gene were included in the study: 
rs17852900, causing a G to T change, and rs1480544, a C/T change. The rs1480544 
polymorphism affects a putative regulatory element, an exonic splicing silencer, consequently it 
is thought to affect mRNA and peptide synthesis [72]. This polymorphism was found to be 
significantly more frequent in patients with BM considering both allelic and genotypic 
frequencies. In patients homozygous for the minor allele (TT), a significant decrease was 
detected in the levels of tumor-necrosis factor alpha (TNF-α), interleukin 1 beta (IL1-β), 
macrophage inflammatory protein 1-alpha (MIP-1αCCL3), macrophage inflammatory protein-1-
beta (MIP-1βCCL4) and in the number of cells counted in the collected cerebrospinal fluid 
(CSF), and an increase in immunoglobulin G (IgG) levels. These findings suggest, that 
rs1480544 polymorphism causes impairment in the immune response against virulent agents. The 
C/T change in the exonic splicing silencer region of the gene supposedly affects the expression of 
inflammation markers such as TNF-α, IL1-β, MIP1αCCL3 and MIP1βCCL4, and causes 
impairment in the recruitment of leukocytes. The elevation of IgG levels in patients with TT 
genotype suggests the influence of KYNA on immunoglobulin production, however, by a so far 
unknown mechanism [71].
In addition to de Souza’s findings, Coutinho et al. found elevated KYNA levels in CSF of 
patients with BM carrying the T allele of the rs1480544 polymorphism [73]. A tendency for 
increase in KYNA level could also be noted among CT genotype patients suffering from acute 
BM. These results give support to the assumption that this particular SNP leads to an increase in 
the amount of AADAT mRNA and subsequently causes enhancement of KATII enzyme 
synthesis [73].
In 2015 Fontes et al. searched for possible combinations of genotypes that could have an effect 
on the course of BM [74]. Based on previous findings of de Souza et al., they examined the 
occurrence of the rs1480544 C/T variant of the AADAT gene in combination with 
polymorphisms of genes previously reported to cause impairment in DNA repair mechanisms, 
such as Asn148Glu of Apurinic/Apyrimidinic Endodeoxyribonuclease (APEX1), Ser326Cys of 
8-Oxoguanine DNA Glycosylase (OGG1) and Val762Al of Poly(ADP-Ribose) Polymerase 1 
(PARP1). Results of gene interaction analysis showed a statistically significant combined 
occurrence of these genetic alterations among BM patients, suggesting the possibility of 
synergism existing between different pathways involving these genes in the development and 
course of BM [74].
2.5. Kynurenine 3-monooxygenase 
KMO (Kynurenine 3-monooxygenase, also known as Kynurenine 3-Hydroxylase) (EC 1.14.13.9) 
is a 55 kDa molecular mass protein of more, than 480 amino acids. In the KP it catalyzes the 
KYN to 3-HK conversion. It is mitochondrial flavoprotein, utilizing O2 and NADPH for the 
catalyzed reaction [75]. Downstream of KMO in the pathway are synthetized 3-HAA and QUIN. 
Elevated levels of 3-HK, that is an endogenous oxidative stress generator, have been reported in 
several neurodegenerative disorders [69][76]. In contrast to 3-HK, 3-HAA may be 
neuroprotective due to its hemeoxygenase-1 (HO-1) inducing effects in astrocytes. HO-1 an 
antioxidant enzyme with anti-inflammatory and cytoprotective features [77]. In the central 
nervous system QUIN acts as a neurotoxin, via activating NMDA receptors, thus creating an 
enormous calcium influx into astrocytes and neurons causing cells damage [78]. QUIN has an 
effect on the appearance of depressive symptoms by inducing the nitric oxide - cyclic guanosine 
monophosphate (NO-cGMP) pathway, promoting oxidative stress and interfering the translation 
of brain derived neurotrophic factor [79]. 
The KMO gene in humans is localized on the long arm of chromosome 1. It is 63 759 nucleotides 
long and consist of 17 exons. KMO is coded on chromosome 13 in rat and on chromosome 1 in 
mice.
2.5.1. Diseases related to the genetic alterations of kynurenine 3-monooxygenase gene
Several studies have reported linkage between genetic loci on the long arm of chromosome 1 and 
psychiatric disorders with psychotic symptoms, such as bipolar disorder and schizophrenia 
(Fig.1) [80][81][82]. Since the KMO gene is located in that locus, it became a candidate in the 
eye of researchers looking for a predisposing factor for the diseases mentioned above. Results 
obtained from postmortem tissue analysis of schizophrenic patients support this suspicion. A 
significant and correlated decrease in the expression of KMO gene and the activity of the KMO 
enzyme was found in brain tissues obtained from schizophrenia patients compared to control 
patients [83]. Data concerning association between genetic alterations of the KMO gene and 
schizophrenia are however, inconclusive, as no linkage could be identified between the presence 
of any one of 15 studied polymorphic forms of the gene and among Scandinavian patients [84] 
(Table 4).
Table 4. 
15 studied polymorphic forms of the gene investigated among Scandinavian 
patients with schizophrenia by Holtze et al.
rs number base change 
rs10926508 A/G
rs2992642 A/C
rs3014572 T/C
rs2050513 C/A
rs3014569 T/C
rs10926513 A/T
rs6661244 C/T
rs6689793 G/C
rs3007737 C/T
rs2065799 C/T
rs3765806 C/G
rs12139441 A/G
rs4660103 G/A
rs850678 A/T
rs1053230 C/T
Among Japanese patients the rs2275163 (a C/T change) polymorphism association with 
schizophrenia was found to be significant both by single-marker comparisons and haplotype 
analysis. However, among a second, independent sample the significance of haplotype 
association could not be reproduced [85].
Results are similar regarding the rs2275163 polymorphism among Russian patients – no 
significant difference was found between the frequency of the minor allele of patients and that of 
healthy controls [86]. However, this study revealed a significant intergroup difference concerning 
another SNP, rs1053230. 
The polymorphism is an A/G base change in exon 15 of the KMO gene, causing an arginine to 
cysteine change at the 452nd amino acid of the enzyme (in fact the nucleotide change in the 
coding sequence is C/T, however the database records the SNP in reverse orientation). The 
frequency of the homozygous minor GG, genotype of rs1053230 polymorphism was significantly 
higher among patients compared to the control group. Interestingly, though the minor allele (T) 
of the other studied SNP rs2275163 did not prove to be a risk factor alone, in combination with 
the GG genotype of rs1053230 it seemed to increase the risk of schizophrenia. The risk of 
schizophrenia among subjects with the GG genotype of the rs1053230 locus combined with at 
least one minor allele of the SNP rs2275163 (either in the form of a CT or TT genotype) was 
shown to be twice as big as in subjects with a different allele combination [86]. Though data 
concerning the association of polymorphism rs2275163 with the incidence of schizophrenia are 
unequivocal, it is likely that is has an impact on the expression of KMO gene. In schizophrenic 
patients with at least one minor allele of the single nucleotide change rs2275163, a slightly higher 
KMO mRNA level could be detected compared to those who had CC genotype [83]. 
Patients homozygous to the major allele of rs2275163 (CC genotype) were found to perform 
poorer in neurocognitive tasks such as predictive pursuit and visuospatial working memory than 
members of the CT genotype subgroup [87][83]. However, when comparing patients with CC 
and TT genotypes, the difference was not significant [83]. It should be mentioned here, that 
among healthy subjects with TT or CT genotypes inequality could also be observed in cognitive 
performance though the difference was again not significant [87]. 
Effects upon cognitive functions were also reported for homozygous carriers SNP rs1053230 
major allele. Similarly to rs2275163, individuals of CC genotype regarding the SNP rs1053230 
reached lower composite scores compared to with CT or TT genotype [87].
Elevated KYNA levels have been reported in the CSF of schizophrenic patients. As KMO is in 
charge of the formation of 3-HK, thus decreasing the amount of KYN available for KYNA 
synthesis, changes in KYNA levels can serve as an indirect indicator of KMO activity [88]. 
Andreassen et al. found, that both in control- and schizophrenic patients the presence of the T 
allele of the SNP rs1053230 (indicated in forward orientation) was associated with a 45% 
increase of KYNA level in the CSF [89].
A decrease in the KMO gene expression was detected in the prefrontal cortex (PFC) of bipolar 
disorder patients with psychotic features compared to patients without psychotic features [90]. 
This observation is in accord with results of postmortem brain tissue analysis of schizophrenic 
patients. However, in contrast with results of studies carried out among schizophrenic patients, 
the C allele of the rs1053230 (forward) polymorphism was found to be more common among 
bipolar disorder patients with psychotic features. The major allele was also associated with higher 
KYNA level in the CSF of bipolar patients accompanied with a reduction in KMO activity. 
HapMap3 project data analysis revealed, that this allele is also associated with a reduction in the 
KMO expression detected in lymphoblastoid cell lines. The link between the C allele of the 
rs1053230 SNP and KMO gene expression can be observed also in epileptic patients [90].
Polymorphism rs1053230 of KMO was found to be significantly associated with postpartum 
depressive symptoms (PDS) in Chinese women. AG genotype women with PDS were found to 
have significantly higher serum 3-HK concentration and 3-HK/KYN ratio compared to those 
with the GG genotype. These findings suggest the possibility of the rs1053230 SNP causing 
higher KMO activity [79].
Genetic alterations of the KMO gene have been investigated besides psychiatric disorders also in 
diseases involving neurodegeneration such as PD and MS.
Török et al. investigated 4 polymorphisms of the KMO gene in search for a genetic link between 
the KP and PD. Two of the examined SNPs (rs2275163, and rs1053230) have been associated 
with psychiatric disorders by other studies (see above). Both of the other two polymorphisms 
(rs2050518 and rs6661244) are localized in intronic regions of the gene, the former one of them 
is an A to T change (rs 2050518), the latter one is a C to T. Neither of these polymorphisms was 
found to be associated with PD in the population studied [91].
In search for genetic alterations contributing to MS, a focused GWA study was carried out 
targeting chromosome 1q43. Two polymorphisms, rs1053221 (A/G) and rs1053183 (C/T) located 
in the KMO gene were found to be in significant association with MS [92].
2.6. Kynureninase/L-Kynurenine Hydrolase
In human, KYNU (EC 3.7.1.3) catalyses the 3-HK/3-HAA conversion. It is expressed in several 
tissues of the body, such as bone marrow and organs of the immune system, kidney and urinary 
bladder, lung, brain, but most abundantly in the liver. It is a large protein, built up of 465 amino 
acids, with a molecular weight over 52 kDa. It functions as a homodimer requiring PLP as a 
cofactor [93]. The gene is almost 307 000 nucleotides. It is located on the long arm of 
chromosome 2 at 22.2 position, and contains 21 exons in man. In mice it localizes to 
chromosome 2, while in rats to chromosome 3.
2.6.1. Diseases related to the genetic alterations of kynureninase gene
In 2007 Christensen et al. reported a family with xanthurenic aciduria (also known as 
hydroxykynureninuria). The diagnosis detected massive urinary excretion of XA, 3-
hydroxykynurenine (3-OHKYN) and KYN in one child and one of his siblings (sibling 1). 
Slightly increased urinary excretion of 3-OHKYN of the mother, father and another sibling 
(sibling 4) each observation suggesting the deficiency of KYNU. Analysis of the KYNU gene 
showed, that both the proband and sibling 4 were homozygous for a minor allele of the 
rs606231307 polymorphism of the gene (Fig. 1), whereas the parents and sibling 1 carried one 
minor, and one major allele. The SNP is an A/G change in the 7 exon of the gene, and causes a 
threonine to alanine amino acid change at the 198 position. The alteration can cause impairment 
in KYNU function, thus leading to the metabolic changes listed above. Impairment in the 
enzymatic function of the KYNU enzyme has already been hypothesized to be the underlying 
cause of xanthurenic aciduria [94][95], however, this was the first case establishing an 
association at molecular genetic level [96].
The involvement of the KP in blood pressure regulation has been confirmed in animal 
experiments. A 40 Hgmm decrease of mean arterial blood pressure could be reached in 
spontaneously hypertensive (SHR) rats – widely used as models for the investigation of human 
hypertension – by injecting KYNA into the rostral ventrolateral medulla of the animals, an area 
with key role in regulating arterial blood pressure [97]. Mizutani et al. hypothesized that high 
blood pressure in SHR rats might be due to malfunction of one of the enzymes related to KYNA 
metabolism. Therefore, they investigated the KYNU gene of the SHR strain, and found an A to G 
change in 1291 position in exon 16, resulting in an isoleucine to valine switch in the enzyme. 
Another nucleotide change – a G to A substitution – was reported in the 11 intron [98]. 
Comparison of the KYNU mRNA levels in the brainstem of SHR animals and animals of a non-
hypertensive strain revealed a higher expression level in rats of the SHR strain. These findings – 
in concert with earlier results of Ito et al. – strongly suggest, that the reported genetic alterations 
of the KYNU gene have an impact on the enzyme function and participate in the development of 
hypertension [98].
Discovering such drastic effects of KYNA in SHR rats, raised questions regarding the 
relationship between blood pressure regulation and the KP in human. In 2005 Zhang et al. 
examined 16 polymorphisms of the KYNU gene among patients diagnosed with essential 
hypertension. An A/G change polymorphism, causing a lysine to glutamic acid change at the 412 
amino acid of the enzyme, was found to be significantly more frequent among hypertensive 
patients than in the control group, considering both allele- and genotype distribution [99].
In a more recent experiment of Zhang et al. a further polymorphism of the KYNU gene was 
found to be in association with essential hypertension. The SNP rs2304705 is a G to A base 
change, which leads to an Arg to Gln switch in the KYNU protein at the 188. Amino acid 
position. The minor allele (GA and AA genotypes) was found to be significantly more frequent 
among patients than in the control group. The overwhelming majority of the patients with GA 
genotype had hypertension in their family history (96,97%), while this ratio was remarkably 
smaller (50%) among the individuals of the control group. Those, who carried the minor allele, 
had significantly higher systolic and diastolic blood pressure, mean arterial pressure and serum 
creatinine level compared to those, who were homozygous to the major allele. Results of the 
genetic analysis of genotype-discordant sibling-pairs were in accordance with the findings 
presented above. Those, who carried the minor allele had significantly higher systolic and 
diastolic blood pressure compared to those, who were homozygous to the major allele (GG 
genotype). In vitro studies also revealed the link between the rs2304705 polymorphism and 
reduced KYNU enzyme activity, finding the Arg188Gln amino acid change to diminish the 
enzyme activity by 50%. Interestingly this association could not be detected in the case of the 
Lys412Glu polymorphism despite its association with essential hypertension (see above) [100].
2.7. 3-hydroxyanthranilate 3,4-dioxygenase
The 3-hydroxyanthranilate 3,4-dioxygenase (3-HAO, EC 1.13.11.6) enzyme catalyzes the 
conversion of 3-HAA acid to QUIN. The gene of 3-HAO is also known as HAAO. It is localized 
at 2p21, with a length over 26 000 bases and it contains 11 exons.
The 286 amino acid enzyme has a molecular mass of 32 kDa. It is found in the cytosol as a 
monomer. 3-HAO can be found in several tissues throughout the body, among others in liver and 
kidney, and it is also expressed in low amounts in the central nervous system [101].
By converting 3-HAA to QUIN the enzyme decreases the amount of a neuroprotective metabolite 
while increases the amount of a product with neurotoxic properties. Therefore, not surprisingly, 
alterations of 3-HAO are found in diseases which are associated with the elevated levels of 
QUIN.2.7.1. Diseases related to the genetic alterations of 3-hydroxyanthranilate 3,4-
dioxygenase gene
Collaborative Study on the Genetics of Alcoholism (COGA) data have shown a linkage between 
the p14-q14.3 region of chromosome 2 and alcohol dependence combined with conduct disorder 
or suicide attempts. Several of the genes found in this region have already been associated with 
the conditions mentioned above. One of these genes is HAAO. In a follow-up study of the COGA 
data SNPs of the HAAO gene were investigated in respect of their linkage to alcohol dependence 
accompanied with conduct disorder or suicide attempts. Out of the 13 investigated 
polymorphisms 6 (rs375554, rs13027051, rs2374442, rs3816184, rs3816182 and rs737148) were 
found to be significantly associated with the diseases (Fig.1) [102].
Another association of an HAAO SNP with a disease was associated by Geller et al. By GWA 
studies they found a significant association between the rs3816183 SNP of the HAAO gene and 
the occurrence of hypospadiasis. This disease is a birth defect, for the development of which the 
contribution of both environmental and genetic risk factors have been identified [61]. The 
rs3816183 polymorphism of HAAO is a C to T change that causes an isoleucine to valine change 
at the 37 amino acid position of the enzyme [103]. Presently it is unknown that through what 
mechanism this alteration results in the development of hypospadiasis.
2.8. Aminocarboxymuconate semialdehyde decarboxylase
The ACMSD (EC 4.1.1.45) is a 38 kDa protein built from 336 amino acids. The encoding gene is 
located on the long arm of chromosome 2. It is 63 729 nucleotides and comprises 13 exons in 
humans. In mice is coded on chromosome 1 while in rat on chromosome 13.
The enzyme can be found in the kidney, liver and brain. It plays a crucial role in the conversion 
of ACMS to 2-aminomuconate-semialdehyde. In case of impaired ACMSD function, the reaction 
shifts in the direction of production of QUIN, and through its neurotoxic properties may 
contributes to the development and progression of diseases such as PD, HD, AD and epileptic 
seizures [12][104][105].
2.8.1. Diseases related to the genetic alterations of aminocarboxymuconate semialdehyde 
decarboxylase gene
Recently Martí-Massó et al. reported on a family suffering from familial cortical myoclonic 
tremor and epilepsy (FCMTE). Symptoms of the patients, such as epileptic seizures, tremor, gait 
disturbances and cognitive impairment – the latter ones are symptoms often related to 
neurodegenerative diseases – turned the attention to the ACMSD gene [106]. Whole Genome 
Sequencing (WGS) revealed a mutation, which results in a premature stop codon (Trp26Stop) 
(Fig. 1). Supported by findings of Fukuoka et al. [107], it is believed, that this genetic alteration 
causes impairment in the enzymatic function. Due to decreased activity of the ACMSD enzyme, 
the pathway is shifted in the direction of QUIN formation. The excessive amount of QUIN can 
explain the symptoms of the patients, as elevated brain QUIN level can lead to the formation of 
epileptic seizures and promote the loss of neurons. This leads to the conclusion that Trp26Stop 
mutation of the ACMSD gene can be a causative genetic alteration in FCMTE [106].
Findings of Martí-Massó et al., specifically the association of ACMSD with the reported patients, 
support the hypothesis of the vulnerability of the nigrostriatal dopaminergic system to the 
alterations of this gene. Such assumption raised after the meta-analysis of GWASs carried out in 
2011 by the International Parkinson Disease Genomics Consortium. The aim of the study was to 
reveal so far unidentified genetic risks for PD. A polymorphism in the ACMSD locus was found 
to have a significant impact on the risk of the development of the neurodegenerative disease 
(Fig.1) [108].
3. Conclusion
The KP plays a pivotal role in the metabolism of Trp. Some of the enzymes of the pathway have 
multiple forms in different tissues of the human body.
In the last decades massive amount of data on the human genome has been accumulated. Results 
of traditional genetic analyses and targeted or non-targeted high throughput GWS revealed causal 
links between disease states and several variants of seven of the KP genes (IDO1/2, TDO2, 
KATII, KMO, KYNU, 3-HAO, ACMSD) that result in expression of KP enzymes in somewhat 
altered forms.
Genetic alterations of the IDO enzymes were found to be associated mainly with such 
autoimmune diseases as CD and systemic sclerosis and disorders related to MDD. Association 
was found between TDO2 gene polymorphisms and hypertryptophanaemia and psychiatric 
disorders. Similarly, based on its chromosomal localization a significant association have been 
established between variants of the KMO gene and such psychiatric disorders as schizophrenia, 
bipolar disorder and PDS. In relation of neurodegenerative diseases link between a KMO SNP 
and MS has been reported, however, the association of any KMO genetic variant to PD so far has 
not been uncovered. Variants of other genes coding for further KP enzymes have been implicated 
as well in numerous malfunctions: KATII alterations were found to be associated with modified 
inflammatory mechanism. The role of KYNU was shown in in essential hypertension and 
xanthurenicaciduria. Variations of the HAAO gene have been linked to alcohol dependence and - 
by a so far unknown mechanism – to hypospadiasis. Finally, a mutation of the gene coding for 
the ACMSD enzyme was found in members of a family with FCMTE and polymorphism of this 
gene are also recognized as a risk factor in PD.
The genetic alterations leading to activity changes of the KP are mostly SNPs, that are present in 
variable frequencies in different population groups. In some cases, the nucleotide change is found 
within the coding regions of KP gene and thus results in amino acid change or early translation 
termination. In a few known cases nucleotide alteration outside of exon affects gene function 
either by modifying RNA splicing and/or translation, or by altering promoter structure thereby 
affecting transcription intensity. In a particular case, a single nucleotide change of the TDO2 
gene causes an amino acid change in a regulatory site of the protein, and leads to the accelerated 
degradation of the enzyme [60].
In addition to well-known effects of KP metabolites, which are primarily modulation of immune 
and inflammatory responses and neurodegeneration, there are several diseases in which enzymes 
or metabolites of the pathway are known or suspected to play roles. Therefore, knowledge on the 
large number of genetic alterations resulting in minor allele variants of genes encoding KP 
enzymes may provide valuable help in prediction, diagnosis and/or prognosis of some of these 
diseases. Moreover, the detection of SNPs affecting KP enzymes might as well help to identify 
these genes and their products of as potential therapeutic targets. 
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Figure legends
Figure 1.
An overview of the KP. The metabolites are indicated with full name. The names of the enzymes 
are given in abbreviated forms. Diseases for which association of genetic alteration(s) resulting in 
malfunction of a particular enzyme has been investigated are listed with references. (Bold: 
association have been found)
 Abbreviations: IDO1,2: Indoleamine-2,3-dioxygenase 1,2; TDO2: Tryptophan 2,3-dioxygenase; 
KAT: Kynurenine aminotransferase; KMO: Kynurenine 3-monooxygenase / Kynurenine 3-
Hydroxylase; KYNU: Kynureninase/L-Kynurenine Hydrolase; 3-HAO: 3-hydroxyanthranilate 
3,4-dioxygenase; ACMSD: Aminocarboxymuconate semialdehyde decarboxylase/Picolinate 
carboxylase; NAD+: Nicotinamide adenine dinucleotide
Figure 2. 
The role of IDO1 in immune regulation
IDO1 expression can be enhanced by cytokines (IL-1, IL-2, IL-4, IL-13, TNFα, TGFβ, IFNα/β/γ) 
and lipopolysaccharides (LPS). IDO1 induction leads to a decrease in tryptophan amount and the 
formation of kynurenine metabolites. By activating regulatory T cells, and via the inhibition of 
effector T cells and natural killer cells, IDO1 plays an important role in the maintenance of 
immune homeostasis, tumor immunity and in the suppression of fetal rejection and 
autoimmunity.


